

    <!DOCTYPE html>
<html class="">

        
<head>
    <title>New drugs in psychiatry: focus on new... | F1000Research</title>
    <meta charset="utf-8">
    <!--<meta http-equiv="Content-Type" content="text/html; charset=utf-8"/>-->
    <!--<meta lang="$locale">-->
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta name="google-site-verification" content="9-QVycOO2_ob3Z9QzRmXv2CF08A9oyYXqWyTiVdKPlU" />
    <!-- This is commented out to fix display problems on mobile devices.
    We may use it again once we implement a responsive design that supports native device resolutions.
    <meta name="viewport" content="width=device-width"> -->

    <meta name="viewport" content="width=device-width, initial-scale=1, maximum-scale=1">



    <link rel="alternate" title="Recent articles published in F1000Research" href="/rss" type="application/rss+xml">
            <link rel="alternate" type="application/pdf" title="PDF" href="https://f1000research.com/articles/6-397/pdf"/>
        <link rel="canonical" href="https://f1000research.com/articles/6-397" />
    
            <meta name="description" content="Read the original article in full on F1000Research: New drugs in psychiatry: focus on new pharmacological targets" />
    
            <meta name="og:title" content="F1000Research Article: New drugs in psychiatry: focus on new pharmacological targets.">
            <meta name="og:description" content="Read the latest article version by Filippo Caraci, Gian Marco Leggio, Salvatore Salomone, Filippo Drago, at F1000Research.">
            <meta name="og:image" content="/img/sharing/og_research.png">
            <meta name="version-id" content="11022">
            <meta name="article-id" content="10233">
            <meta name="dc.title" content="New drugs in psychiatry: focus on new pharmacological targets">
            <meta name="dc.description" content="The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer&rsquo;s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer&rsquo;s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.">
            <meta name="dc.subject" content="psychotropic drugs, cariprazine, vortioxetine, ketamine oresketamine, aducanumab, neuropsychopharmacology, anti-psychotic, ">
            <meta name="dc.creator" content="Caraci, Filippo">
            <meta name="dc.creator" content="Leggio, Gian Marco">
            <meta name="dc.creator" content="Salomone, Salvatore">
            <meta name="dc.creator" content="Drago, Filippo">
            <meta name="dc.date" content="2017/03/30">
            <meta name="dc.identifier" content="doi:10.12688/f1000research.10233.1">
            <meta name="dc.source" content="F1000Research 2017 6:397">
            <meta name="dc.format" content="text/html">
            <meta name="dc.language" content="en">
            <meta name="dc.publisher" content="F1000 Research Limited">
            <meta name="dc.rights" content="https://creativecommons.org/licenses/by/3.0/igo/">
            <meta name="dc.type" content="text">
            <meta name="prism.keyword" content="psychotropic drugs">
            <meta name="prism.keyword" content="cariprazine">
            <meta name="prism.keyword" content="vortioxetine">
            <meta name="prism.keyword" content="ketamine oresketamine">
            <meta name="prism.keyword" content="aducanumab">
            <meta name="prism.keyword" content="neuropsychopharmacology">
            <meta name="prism.keyword" content="anti-psychotic">
            <meta name="prism.publication.Name" content="F1000Research">
            <meta name="prism.publicationDate" content="2017/03/30">
            <meta name="prism.volume" content="6">
            <meta name="prism.number" content="397">
            <meta name="prism.versionIdentifier" content="1">
            <meta name="prism.doi" content="10.12688/f1000research.10233.1">
            <meta name="prism.url" content="https://f1000research.com/articles/6-397">
            <meta name="citation_title" content="New drugs in psychiatry: focus on new pharmacological targets">
            <meta name="citation_abstract" content="The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer&rsquo;s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer&rsquo;s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.">
            <meta name="citation_description" content="The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer&rsquo;s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer&rsquo;s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder.">
            <meta name="citation_keywords" content="psychotropic drugs, cariprazine, vortioxetine, ketamine oresketamine, aducanumab, neuropsychopharmacology, anti-psychotic, ">
            <meta name="citation_journal_title" content="F1000Research">
            <meta name="citation_author" content="Filippo Caraci">
            <meta name="citation_author_institution" content="Department of Drug Sciences, University of Catania, Catania, Italy">
            <meta name="citation_author_institution" content="IRCCS Associazione Oasi Maria S.S., Institute for Research on Mental Retardation and Brain Aging, Troina (EN), Italy">
            <meta name="citation_author" content="Gian Marco Leggio">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy">
            <meta name="citation_author" content="Salvatore Salomone">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy">
            <meta name="citation_author" content="Filippo Drago">
            <meta name="citation_author_institution" content="Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy">
            <meta name="citation_publication_date" content="2017/03/30">
            <meta name="citation_volume" content="6">
            <meta name="citation_publication_number" content="397">
            <meta name="citation_version_number" content="1">
            <meta name="citation_doi" content="10.12688/f1000research.10233.1">
            <meta name="citation_firstpage" content="397">
            <meta name="citation_pdf_url" content="https://f1000research.com/articles/6-397/v1/pdf">
    

    
    <link href="/img/favicon-research.ico" rel="shortcut icon" type="image/ico">
    <link href="/img/favicon-research.ico" rel="icon" type="image/ico">

        <link rel="stylesheet" href="/1597255280893/css/mdl/material-design-lite.css" type="text/css" media="all" />
    <link href="https://fonts.googleapis.com/icon?family=Material+Icons" rel="stylesheet">
    <link href="https://fonts.googleapis.com/css?family=Roboto:100,100i,300,300i,400,400i,500,500i,700,700i,900,900i" rel="stylesheet">
    <link rel="stylesheet" href="https://cdnjs.cloudflare.com/ajax/libs/MaterialDesign-Webfont/2.2.43/css/materialdesignicons.min.css" />

        
            
    <link rel="stylesheet" href="/1597255280893/css/F1000Research.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons.css" type="text/css" media="all" />
    <link rel="stylesheet" href="/css/F1000ResearchFontIcons/animation.css" type="text/css" media="all" />

        <!--[if IE 7]><link rel="stylesheet" href="/css/F1000ResearchFontIcons/F1000ResearchFontIcons-ie7.css" media="all" /><![endif]-->

                    <script>dataLayer = [];</script>
        <!-- Google Tag Manager -->
        <script>(function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start':
        new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0],
        j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src=
        'https://www.googletagmanager.com/gtm.js?id='+i+dl;f.parentNode.insertBefore(j,f);
        })(window,document,'script','dataLayer','GTM-54Z2SBK');</script>
        <!-- End Google Tag Manager -->
    
    <script src="https://ajax.googleapis.com/ajax/libs/jquery/1.8.1/jquery.min.js"></script>
    <script>window.jQuery || document.write('<script src="/js/vendor/jquery-1.8.1.min.js"><\/script>')</script>
    <script src="/1597255280893/js/vendor/modernizr-2.6.1-respond-1.1.0.min.js"></script>
    <script src="/1597255280893/js/shared_scripts/sticky.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/shared_scripts/menu.js"></script>
    <script src="/1597255280893/js/shared_scripts/navbar.js"></script>
    <script src="/1597255280893/js/shared_scripts/platforms.js"></script>
    <script src="/1597255280893/js/shared_scripts/object-polyfills.js"></script>
            <script src="/1597255280893/js/vendor/lodash.min.js"></script>
        <script>CKEDITOR_BASEPATH='https://f1000research.com/js/ckeditor/'</script>
    <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/plugins.js"></script>
    <script src="/1597255280893/js/shared_scripts/helpers.js"></script>
    <script src="/1597255280893/js/app/research.js"></script>
    <script>window.reactTheme = 'research';</script>
    <script src="/1597255280893/js/public/bundle.js"></script>

    <script src="/1597255280893/js/app/research.ui.js"></script>
    <script src="/1597255280893/js/app/login.js"></script>
    <script src="/1597255280893/js/app/main.js"></script>
    <script src="/1597255280893/js/app/js-date-format.min.js"></script>
    <script src="/1597255280893/js/app/search.js"></script>
    <script src="/1597255280893/js/app/cookies_warning.js"></script>
    <script src="/1597255280893/js/mdl/mdl.min.js"></script>

    <script src="https://cdnjs.cloudflare.com/ajax/libs/mathjax/2.7.1/MathJax.js?config=TeX-AMS-MML_HTMLorMML"></script>
                <script src="https://f1000researchdata.s3-eu-west-1.amazonaws.com/js/ckeditor.js"></script>
            <script src="/js/ckeditor/adapters/jquery.js"></script>
                <script src="/js/article/article_scrolling_module.js"></script>
            <script src="/js/article/article_stats.js"></script>
            <script src="/js/article/article.js"></script>
            <script src="/js/shared_scripts/referee_timeline_pagination.js"></script>
            <script src="/js/app/text_editor_controller.js"></script>
            <script src="//s7.addthis.com/js/250/addthis_widget.js#pubid=ra-503e5e99593dc42c"></script>
            <script src="/js/article/article_metrics.js"></script>
        
                                                                            <script>
            if (window.location.hash == '#_=_'){
                window.location = window.location.href.split('#')[0]
            }
        </script>

                    
        
    <!-- pixelId: 1641728616063202 :: assetPixelId: 6034867600215 :: funderPixelId:  -->

            <!-- Facebook pixel code (merged with EP GTM code) -->
        <script>
            !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function()

            {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)}
            ;if(!f._fbq)f._fbq=n;
            n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0;
            t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window,
            document,'script','https://connect.facebook.net/en_US/fbevents.js');

            fbq('init', '1641728616063202');

            
            fbq('track', "PixelInitialized", {});
        </script>

        <noscript><img height="1" width="1" style="display:none"
            src="https://www.facebook.com/tr?id=1641728616063202&noscript=1&amp;ev=PixelInitialized"
        /></noscript>
        <!-- End Facebook Pixel Code -->
    
                <script>
            (function(h,o,t,j,a,r){
                h.hj=h.hj||function(){(h.hj.q=h.hj.q||[]).push(arguments)};
                h._hjSettings={hjid:917825,hjsv:6};
                a=o.getElementsByTagName('head')[0];
                r=o.createElement('script');r.async=1;
                r.src=t+h._hjSettings.hjid+j+h._hjSettings.hjsv;
                a.appendChild(r);
            })(window,document,'https://static.hotjar.com/c/hotjar-','.js?sv=');
        </script>
    
</head>
<body  class="o-page-container no-js p-article o-layout-reset   ">

    
                            <!-- Google Tag Manager (noscript) -->
        <noscript><iframe src="https://www.googletagmanager.com/ns.html?id=GTM-54Z2SBK"
        height="0" width="0" style="display:none;visibility:hidden"></iframe></noscript>
        <!-- End Google Tag Manager (noscript) -->
    
        
    <div class="o-page">

        <div id="notify-container"></div>
        <div id="pageWarning"></div>
        <div id="pageMessage"></div>
        <div id="pageFooterMessage"></div>

                                <div id="f1r-ga-data" data-name="f1r-ga-data" class="f1r-ga-data"
                data-user-registered="false"
                data-user-module=""
                data-current-path=""
                data-location=""
                data-website="F1000Research"
                data-websiteDisplayName="F1000Research">
            </div>
        
                
        
        <div class="header-wrapper   js-navbar-space ">
                            


    










        
                            
    
            



<nav class="c-navbar js-navbar js-mini-nav js-sticky c-navbar--js-sticky c-navbar--userSite c-navbar__platform-bgcolor  c-navbar--bg-f1000research ">

    <div class="c-navbar__content">

                                <div class="c-navbar__extras">
            <div class="o-wrapper">
                <div class="o-actions o-actions--middle c-navbar__extras-row">
                    <div class="o-actions__primary">
                        
                                            </div>
                                    </div>
            </div>
        </div>

        <div class="o-wrapper t-inverted js-sticky-start">

            <div class="c-navbar__branding-row">
                <div class="c-navbar__row">


                                        
                    <div class="c-navbar__primary u-mr--2">

                                                                                                                                                                                                    <a href="/" class="c-navbar__branding u-ib u-middle"   data-test-id="nav_branding"  >
                                <img class="u-ib u-middle" src="/img/research/F1000Research_white_solid.svg" alt="F1000Research">
                            </a>
                                            </div>

                    <div class="c-navbar__secondary c-navbar__row">


                                                
                                                    <form action="/search" class="-navbar__secondary u-mr--2 c-search-form js-search-form u-hide u-show@navbar">
                                <label for="searchInput" class="c-search-form__label _mdl-layout">
                                    <input name="q" type="search" class="c-search-form__input" id="searchInput" placeholder="Search">
                                    <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                </label>
                            </form>
                        
                                                
                                                    <div class="c-navbar__primary u-hide u-show@navbar">
                                <div class="_mdl-layout c-navbar__cta">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--no-shadow mdl-button--multi-line mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                            </div>
                        

                                                
                        <span class="u-hide@navbar _mdl-layout u-nowrap">

                                                            <button type="button" class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" data-focus="#navbar_mob_search_input" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_search_mob"  ><i class="material-icons">search</i></button>
                            
                                                            <button class="mdl-button mdl-js-button mdl-js-ripple-effect mdl-button--icon mdl-button--multi-line c-navbar__toggle c-navbar__toggle--menu js-navbar-toggle" type="button" data-toggle="navbarMenu" data-target="navbarMenu" aria-controls="navbarMenu" aria-expanded="false" aria-label="Toggle navigation"   data-test-id="nav_menu_toggle_mob"  >
                                    <i class="material-icons c-navbar__toggle-open">menu</i>
                                    <i class="material-icons c-navbar__toggle-close">close</i>
                                </button>
                                                    </span>
                    </div>

                </div>
            </div>

                        
                            <div class="c-navbar__menu-row js-navbar-block is-collapsed" id="navbarMenu">

                                                                                                                                                
                                                                    
                                                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                        
                                            

                                                                
                                                                                                                                                                                                                                
                                            
                    <div class="c-navbar__menu-row-content">

                                                                            <div class="u-hide@navbar c-navbar__menu-bar-spacing">
                                <form action="/search" class="c-search-form js-search-form">
                                    <label for="navbar_mob_search_input" class="c-search-form__label _mdl-layout">
                                        <input id="navbar_mob_search_input" name="q" type="search" class="c-search-form__input" placeholder="Search">
                                        <button type="submit" class="c-search-form__submit mdl-button mdl-js-button mdl-button--icon"><i class="material-icons">search</i></button>
                                    </label>
                                </form>
                            </div>
                        
                        <div class="o-actions o-actions--middle">

                            <div class="o-actions__primary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="main-menu"   role="menubar" aria-label="Main Navigation"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/browse/articles" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="0"
                              data-test-id="nav_browse"                              >Browse</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/gateways" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_gatewaysViewAndBrowse"                              >Gateways & Collections</a>

                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="2"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_for-authors"                              >How to Publish</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="How to Publish">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_submit-manuscript"                      href="/for-authors/publish-your-research"
                    role="menuitem"
                    tabindex="0">Submit your Research</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/for-authors/my-submissions"
                    role="menuitem"
                    tabindex="-1">My Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines"                      href="/for-authors/article-guidelines"
                    role="menuitem"
                    tabindex="-1">Article Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-guidelines-new-versions"                      href="/for-authors/article-guidelines-new-versions"
                    role="menuitem"
                    tabindex="-1">Article Guidelines (New Versions)</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_data-guidelines"                      href="/for-authors/data-guidelines"
                    role="menuitem"
                    tabindex="-1">Data Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_asset-guidelines"                      href="/for-authors/posters-and-slides-guidelines"
                    role="menuitem"
                    tabindex="-1">Posters and Slides Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_document-guidelines"                      href="/for-authors/document-guidelines"
                    role="menuitem"
                    tabindex="-1">Document Guidelines</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_article-processing-charges"                      href="/for-authors/article-processing-charges"
                    role="menuitem"
                    tabindex="-1">Article Processing Charges</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_finding-referees"                      href="/for-authors/tips-for-finding-referees"
                    role="menuitem"
                    tabindex="-1">Finding Article Reviewers</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="3"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="-1"
                              data-test-id="nav_about-contact"                              >About</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="About">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_about-page"                      href="/about"
                    role="menuitem"
                    tabindex="0">How it Works</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_referee-guidelines"                      href="/for-referees/guidelines"
                    role="menuitem"
                    tabindex="-1">For Reviewers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_advisoryPanel"                      href="/advisors"
                    role="menuitem"
                    tabindex="-1">Our Advisors</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_policy-page"                      href="/about/policies"
                    role="menuitem"
                    tabindex="-1">Policies</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_glossary-page"                      href="/glossary"
                    role="menuitem"
                    tabindex="-1">Glossary</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_faqs-page"                      href="/faqs"
                    role="menuitem"
                    tabindex="-1">FAQs</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              u-hide u-show@navbar"
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      u-hide u-show@navbar"
                                          data-test-id="nav_for-developers"                      href="/developers"
                    role="menuitem"
                    tabindex="-1">For Developers</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_newsroom-page"                      href="/newsroom"
                    role="menuitem"
                    tabindex="-1">Newsroom</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_contact-page"                      href="/contact"
                    role="menuitem"
                    tabindex="-1">Contact</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="4"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="https://blog.f1000.com/blogs/f1000research/" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                             target="_blank"                                                         tabindex="-1"
                              data-test-id="nav_blog"                              >Blog</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                            <div class="o-actions__secondary">

                                                                
    <ul class="c-menubar c-navbar__menu-bar js-main-menu"   id="secondary-items"   role="menubar" aria-label="My Account"  data-menu-group="navbar" >

        
            
                                                                
                                
                                
                                    <li role="none"
                        data-index="0"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                               c-menubar__item--selected c-navbar__menu-bar-item--parent ">

                        <a href="#" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                         aria-haspopup="true" aria-expanded="false"                             tabindex="0"
                              data-test-id="nav_my-research"                              >My Research</a>

                                                    
    <ul class="c-menu js-menu
                is-collapsed                c-menubar__menu c-navbar__menu"
                  role="menu"
        aria-label="My Research">

        
            
                                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-submissions"                      href="/login?originalPath=/my/submissions"
                    role="menuitem"
                    tabindex="0">Submissions</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-email-alerts"                      href="/login?originalPath=/my/email-alerts"
                    role="menuitem"
                    tabindex="-1">Content and Tracking Alerts</a>

                </li>

                    
            
                
                                
                <li class="c-menu__item js-menu-item
                                              "
                        role="none">

                <a  class="c-menu__link js-menu-link
                                                      "
                                          data-test-id="nav_my-user-details"                      href="/login?originalPath=/my/user-details"
                    role="menuitem"
                    tabindex="-1">My Details</a>

                </li>

                        </ul>
                                            </li>
                
            
        
            
                                                                
                
                                
                                    <li role="none"
                        data-index="1"
                        class="c-menubar__item js-menu-item  c-navbar__menu-bar-item
                                                              ">

                        <a href="/login?originalPath=/articles/6-397.html" class="c-navbar__menu-bar-link js-menu-link " role="menuitem"
                                                                                    tabindex="-1"
                              data-test-id="nav_sign-in"                              >Sign In</a>

                                            </li>
                
            
        
    </ul>



                            </div>

                                                                                        <div class="_mdl-layout c-navbar__cta u-hide@navbar c-navbar__menu-bar-spacing">
                                    <a class="mdl-button mdl-js-button mdl-button--raised mdl-button--multi-line mdl-button--no-shadow mdl-js-ripple-effect mdl-button--inverted c-navbar__submit" href="/for-authors/publish-your-research"   data-test-id="nav_submit_research_mob"  ><i class="material-icons">file_upload</i>Submit your research</a>
                                </div>
                                                    </div>

                    </div>

                </div>
            
        </div>

    </div>

</nav>
                    </div>

        <div class="content-wrapper o-page__main row ">
            <div id="highlight-area" class="content ">
                





<div id=article-metadata class=hidden> <input type=hidden name=versionId value=11022 /> <input type=hidden id=articleId name=articleId value=10233 /> <input type=hidden id=xmlUrl value="/articles/6-397/v1/xml"/> <input type=hidden id=xmlFileName value="-6-397-v1.xml"> <input type=hidden id=article_uuid value=58ff8232-e6ad-4330-a658-d1a5c9b8dcf5 /> <input type=hidden id=referer value=""/> <input type=hidden id=meta-article-title value="New drugs in psychiatry: focus on new pharmacological targets"/> <input type=hidden id=workspace-export-url value="https://sciwheel.com/work/api/import/external?doi=10.12688/f1000research.10233.1"/> <input type=hidden id=versionDoi value="10.12688/f1000research.10233.1"/> <input type=hidden id=usePmcStats value=true /> </div> <main class="o-wrapper p-article__wrapper js-wrapper"> <script type="application/ld+json">
{
  "@context": "https://schema.org",
  "@type": "ScholarlyArticle",
  "mainEntityOfPage": {
    "@type": "WebPage",
    "@id": "https://f1000research.com/articles/6-397"
  },
  "headline": "New drugs in psychiatry: focus on new pharmacological targets",
  "datePublished": "2017-03-30T09:37:51",
  "dateModified": "2017-03-30T09:37:51",
  "author": [
    {
      "@type": "Person",
      "name": "Filippo Caraci"
    },    {
      "@type": "Person",
      "name": "Gian Marco Leggio"
    },    {
      "@type": "Person",
      "name": "Salvatore Salomone"
    },    {
      "@type": "Person",
      "name": "Filippo Drago"
    }  ],
  "publisher": {
    "@type": "Organization",
    "name": "F1000Research",
    "logo": {
      "@type": "ImageObject",
      "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
      "height": 480,
      "width": 60
    }
  },
  "image": {
    "@type": "ImageObject",
    "url": "https://f1000research.com/img/AMP/F1000Research_image.png",
    "height": 1200,
    "width": 150
  },
  "description": "The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer&rsquo;s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer&rsquo;s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder."
}
</script> <div class="o-layout o-layout--right-gutter"> <div id=article_secondary-column class="p-article__main o-layout__item u-font-size--legal u-2/3@article not-expanded "> <div class=float-left> <script type="application/ld+json">
  {
    "@context": "http://schema.org",
    "@type": "BreadcrumbList",
    "itemListElement": [
              {
          "@type": "ListItem",
          "position": "1",
          "item": {
            "@id": "https://f1000research.com/",
            "name": "Home"
          }
        },              {
          "@type": "ListItem",
          "position": "2",
          "item": {
            "@id": "https://f1000research.com/browse/articles",
            "name": "Browse"
          }
        },              {
          "@type": "ListItem",
          "position": "3",
          "item": {
            "@id": "https://f1000research.com/articles/6-397/v1",
            "name": "New drugs in psychiatry: focus on new pharmacological targets"
          }
        }          ]
  }
  </script> <div class="breadcrumbs js-breadcrumbs"> <a href="/" class=f1r-standard-link>Home</a> <span class=item_separator></span> <a href="/browse/articles" class=f1r-standard-link>Browse</a> <span class=item_separator></span> New drugs in psychiatry: focus on new pharmacological targets </div> </div> <div class="article-badges-container u-mb--2"> <div class=crossmark-new> <script src="https://crossmark-cdn.crossref.org/widget/v2.0/widget.js"></script> <a data-target=crossmark><img height=30 width=150 src="https://crossmark-cdn.crossref.org/widget/v2.0/logos/CROSSMARK_Color_horizontal.svg"/></a> </div> <div id=crossmark-dialog style="display: none;" title=""> <iframe id=crossmark-dialog-frame frameborder=0></iframe> </div> <div class=clearfix></div> </div> <div class=article-interaction-container> <div id=main-article-count-box class=article-count-box> <div class="article-metrics-wrapper metrics-icon-wrapper" data-version-id=11022 data-id=10233 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10233.1" data-recommended="" data-doi="10.12688/f1000research.10233.1" data-f1r-ga-helper="Article Page Metrics (Desktop)"> <span class="metrics-on-browse article-metrics-icon f1r-icon icon-89_metrics"></span> <div class="count-title article-metrics-text">ALL Metrics</div> <div class=js-article-metrics-container></div> </div> <div> <div class=count-delimiter></div> <div title="Total views from F1000Research and PubMed Central"> <div class="count-container view-count js-views-count">-</div> <div class=count-title><span class="count-title-icon count-title-views-icon"></span>Views</div> </div> <div class=download-counts hidden> <div class=count-delimiter></div> <div title="Total downloads from F1000Research and PubMed Central"> <div class="count-container js-downloads-count"></div> <div class=count-title><span class="count-title-icon f1r-icon icon-76_download_file"></span>Downloads</div> </div> </div> </div> </div> <div id=main-article-interaction-box class="article-interaction-box has-control-tab"> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-102_download_pdf"></span> <a href="https://f1000research.com/articles/6-397/v1/pdf?article_uuid=58ff8232-e6ad-4330-a658-d1a5c9b8dcf5" title="Download PDF" class="button-link download pdf-download-helper" target=_blank>Get PDF</a> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-103_download_xml"></span> <a id=download-xml href="#" class="button-link download" title="Download XML">Get XML</a> </div> </div> <div class="article-interaction-info article-page"> <div class="cite-article-popup-wrapper article-page-interaction-box"> <div class="article-interaction-button cite-article-button" title="Cite this article" data-windowref=cite-article-popup-10233-1> <span class="f1r-icon icon-82_quote"></span> <a href="#" class="button-link cite-article-popup-link" title="Cite Article">Cite</a> </div> <div id=cite-article-popup-10233-1 class="popup-window-wrapper is-hidden"> <div class=cite-popup-background></div> <div class="popup-window top-popup cite-this-article-box research-layout"> <div class="popup-window-title small cite-title">How to cite this article</div> <span id=cite-article-text-10233-1 data-test-id=copy-citation_text> <span class="article-title-and-info in-popup">Caraci F, Leggio GM, Salomone S and Drago F. New drugs in psychiatry: focus on new pharmacological targets [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):397 (<a class=new-orange href="https://doi.org/10.12688/f1000research.10233.1" target=_blank>https://doi.org/10.12688/f1000research.10233.1</a>) </span> <div class="popup-window-title small margin-top-20 margin-bottom-20 note"> <strong>NOTE:</strong> it is important to ensure the information in square brackets after the title is included in all citations of this article. </div> <div class=float-right> <button class="secondary no-fill orange-text-and-border margin-right-20 close-cite-popup uppercase">Close</button> <button id=copy-citation-details class="secondary orange copy-cite-article-version uppercase js-clipboard" title="Copy the current citation details to the clipboard." data-clipboard-target="#cite-article-text-10233-1" data-test-id=copy-citation_button>Copy Citation Details</button> </div> </div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-76_download_file"></span> <a id=export-citation href="#" class="button-link download" title="Export Citation">Export</a> </div> <div class="modal-window-wrapper is-hidden"> <div id=export-citation-popup class="modal-window padding-20"> <div class=modal-window-close-button></div> <div class=modal-window-title>Export Citation</div> <div class=modal-window-row> <div> <input type=radio name=export-citation-option value=WORKSPACE /> <span class=radio-label>Sciwheel</span> </div> <div> <input type=radio name=export-citation-option value=ENDNOTE /> <span class=radio-label>EndNote</span> </div> <div> <input type=radio name=export-citation-option value=REF_MANAGER /> <span class=radio-label>Ref. Manager</span> </div> <div> <input type=radio name=export-citation-option value=BIBTEX /> <span class=radio-label>Bibtex</span> </div> <div> <input type=radio name=export-citation-option value=PROCITE /> <span class=radio-label>ProCite</span> </div> <div> <input type=radio name=export-citation-option value=SENTE /> <span class=radio-label>Sente</span> </div> </div> <div class=modal-window-footer> <button class=general-white-orange-button id=export-citation-submit>EXPORT</button> </div> <div class=default-error style="display: none;">Select a format first</div> </div> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-90_track"></span> <a class="button-link track-article" data-article-id=10233 id=track-article-signin-10233 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10233?target=/articles/6-397/v1">Track</a> </div> </div> <div class="article-interaction-info article-page"> <div class="article-interaction-button email-article"> <span class="f1r-icon icon-6_email"></span> <a href="#" class=button-link title="Email this article">Email</a> </div> <div class="email-article-version-container small-tooltip _chrome-fix"> <div class=close-icon><span class="f1r-icon icon-3_close_big"></span></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11022 /> <input name=articleId type=hidden value=10233 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> <div class="article-interaction-info article-page"> <div class=article-interaction-button> <span class="f1r-icon icon-34_share"></span> <a href="#" class="button-link last addthis_button share-article" title="Share this article">Share</a> </div> </div> </div> <div id=article-interaction-control-tab class=article-interaction-control-tab> <div id=hide-article-interaction class=article-interaction-control title="Hide Toolbox">&#9644;</div> <div id=show-article-interaction class="article-interaction-control open" title="Show Toolbox">&#10010;</div> </div> </div> <div class="article-header-information article-page"> <div class="f1r-article-mobile article-heading-bar"></div> <div class="article-type article-display">Review </div> <div class="article-title-and-info article-view highlighted-article" id=anchor-title> <h1>New drugs in psychiatry: focus on new pharmacological targets</h1><span class=other-info> [version 1; peer review: 3 approved]</span> </div> <div class=article-subtitle></div> <div class=f1r-article-desk> <div class="authors _mdl-layout"><span class=""><a href="mailto:carafil@hotmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Caraci</span></a><a href="https://orcid.org/0000-0002-9867-6054" target=_blank id=author-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9867-6054</div><sup>1,2</sup>,&nbsp;</span><span class="">Gian Marco Leggio<sup>3</sup>,&nbsp;</span><span class="">Salvatore Salomone<sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:fdrago@unict.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Drago</span></a><a href="https://orcid.org/0000-0003-2887-5223" target=_blank id=author-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=author-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2887-5223</div><sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class="authors _mdl-layout"><span class=""><a href="mailto:carafil@hotmail.com" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Caraci</span></a><a href="http://orcid.org/0000-0002-9867-6054" target=_blank id=mauthor-orcid-0><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-0><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0002-9867-6054</div><sup>1,2</sup>,&nbsp;</span><span class="">Gian Marco Leggio<sup>3</sup>,&nbsp;</span><span class="">Salvatore Salomone<sup>3</sup>,&nbsp;</span><span class=""><a href="mailto:fdrago@unict.it" title="Send email" class="cauthor research-layout"><span class='f1r-icon icon-6_email orange'></span><span>Filippo Drago</span></a><a href="http://orcid.org/0000-0003-2887-5223" target=_blank id=mauthor-orcid-3><span class=orcid-logo-for-author-list></span></a><div class="mdl-tooltip mdl-tooltip--wider" for=mauthor-orcid-3><span class=orcid-logo-for-author-list></span> https://orcid.org/0000-0003-2887-5223</div><sup>3</sup></span></div> </div> <div class=f1r-article-mobile> <div class=article-pubinfo-mobile> PUBLISHED 30 Mar 2017 </div> </div> <span class=Z3988 title="ctx_ver=Z39.88-2004&amp;rft_val_fmt=info:ofi/fmt:kev:mtx:journal&amp;rft_id=info:doi/10.12688%2Ff1000research.10233.1"></span> <div class=f1r-article-desk> <div class="contracted-details first"> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Drug Sciences, University of Catania, Catania, Italy<br/> <sup>2</sup> IRCCS Associazione Oasi Maria S.S., Institute for Research on Mental Retardation and Brain Aging, Troina (EN), Italy<br/> <sup>3</sup> Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy<br/> <p> </p> </div> </div> </div> <div class=f1r-article-mobile> <div class="article-page-section-box margin-bottom-40 research-layout"> <span class=box-title> <span class="f1r-icon icon-85_peer_review"></span> OPEN PEER REVIEW </span> <button class="tertiary grey float-right" data-scrollto=article-reports>DETAILS</button> <div class="status-row referee-reports-container"> REVIEWER STATUS <span class=status-icons> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=12420-19542></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19889-19545></span> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved data-refInfo=19122-19544></span> </span> </div> </div> </div> </div> <h2 class="article-headings article-page-abstract" id=anchor-abstract> <span class="f1r-article-mobile-inline abstract-heading-border"></span> Abstract </h2> <div class="article-abstract article-page-general-text-mobile research-layout"> <div class="abstract-text is-expanded"> The approval of psychotropic drugs with novel mechanisms of action has been rare in recent years. To address this issue, further analysis of the pathophysiology of neuropsychiatric disorders is essential for identifying new pharmacological targets for psychotropic medications. In this report, we detail drug candidates being examined as treatments for psychiatric disorders. Particular emphasis is placed on agents with novel mechanisms of action that are being tested as therapies for depression, schizophrenia, or Alzheimer’s disease. All of the compounds considered were recently approved for human use or are in advanced clinical trials. Drugs included here are new antipsychotic medications endowed with a preferential affinity at dopamine D3 receptor (cariprazine) or at glutamatergic or cannabinoid receptors, as well as vortioxetine, a drug approved for managing the cognitive deficits associated with major depression. New mechanistic approaches for the treatment of depression include intravenous ketamine or esketamine or intranasal esketamine. As for Alzheimer’s disease, the possible value of passive immunotherapy with agents such as aducanumab is considered to be a potential disease-modifying approach that could slow or halt the progressive decline associated with this devastating disorder. </div> <div class=abstract-for-mobile> <div class="margin-top-30 padding-bottom-30 research-layout is-centered"> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border show" style="display: none;"> READ ALL <span class="f1r-icon icon-14_more_small orange vmiddle big"></span> </button> <button class="primary orange-text white-bg bigger-text abstract-expand-button-mobile with-border hide"> READ LESS <span class="f1r-icon icon-10_less_small orange vmiddle big"></span> </button> </div> </div> </div> <div class=clearfix></div> <div class="article-context no-divider"> <div class="article-abstract article-page-general-text-mobile research-layout generated-article-body"> <h2 class=main-title>Keywords</h2> <p class="u-mb--0 u-pb--2"> psychotropic drugs, cariprazine, vortioxetine, ketamine oresketamine, aducanumab, neuropsychopharmacology, anti-psychotic, </p> </div> </div> <div class=article-information> <span class="info-separation padding-bottom"> <div id=corresponding-author-icon class="email-icon float-left"> <span class="f1r-icon icon-6_email orange"></span> <div id=corresponding-author-window class="margin-top-20 popup-window-wrapper is-hidden"> <div class="popup-window corresponding-authors-popup"> <div class=corresponding-author-container> <div class="popup-window-title small">Corresponding Author(s)</div> <div class=authors> Filippo Caraci (<a href="mailto:carafil@hotmail.com">carafil@hotmail.com</a>) <br> Filippo Drago (<a href="mailto:fdrago@unict.it">fdrago@unict.it</a>) </div> </div> <div class="margin-top margin-bottom float-left"> <button id=close-popup-window class=general-white-orange-button>Close</button> </div> </div> </div> </div> <span class="icon-text float-left" data-test-id=box-corresponding-author> <b>Corresponding authors:</b> Filippo Caraci, Filippo Drago </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom competing-interests-display"> <span class=competing-interests-title>Competing interests:</span> The author(s) declare that they have no competing interests. </span> <div class="info-separation padding-bottom grant-information-display"> <span class=grant-information-title>Grant information:</span> The author(s) declared that no grants were involved in supporting this work. </div> <span class="f1r-article-desk info-separation padding-bottom"> <span class="copywrite-icon float-left"> <span class="f1r-icon icon-100_open_access"></span> </span> <span class="icon-text float-left" data-test-id=box-copyright-text> <b>Copyright:</b>&nbsp; © 2017 Caraci F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </span> <div class=clearfix></div> </span> <span class="info-separation padding-bottom" data-test-id=box-how-to-cite> <b>How to cite:</b> <span class="article-title-and-info in-article-box"> Caraci F, Leggio GM, Salomone S and Drago F. New drugs in psychiatry: focus on new pharmacological targets [version 1; peer review: 3 approved]</span>. <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):397 (<a href="https://doi.org/10.12688/f1000research.10233.1" target=_blank>https://doi.org/10.12688/f1000research.10233.1</a>) </span> <span class=info-separation data-test-id=box-first-published><b>First published:</b> 30 Mar 2017, <b>6</b>(F1000 Faculty Rev):397 (<a href="https://doi.org/10.12688/f1000research.10233.1" target=_blank>https://doi.org/10.12688/f1000research.10233.1</a>)</span> <span class=info-separation data-test-id=box-latest-published><b>Latest published:</b> 30 Mar 2017, <b>6</b>(F1000 Faculty Rev):397 (<a href="https://doi.org/10.12688/f1000research.10233.1" target=_blank>https://doi.org/10.12688/f1000research.10233.1</a>)</span> </div> <div class=clearfix></div> <div id=article-context class=article-context> <div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e213>Introduction</h2><p class="" id=d9379e216>Epidemiological data indicate neuropsychiatric disorders as being some of the most prevalent, devastating, and yet poorly treated illnesses. As the approval of central nervous system drugs with novel mechanisms of action has been rare in recent years, there is a critical need to enhance drug discovery in neuropsychopharmacology<sup><a href="#ref-1">1</a></sup>. To achieve this goal, it is essential to focus on developing drugs that target the pathophysiology underlying the disease, which increases the likelihood of identifying efficacious agents rather than symptomatic treatments. The pathology-to-drug discovery approach specifies that an understanding of the pathophysiology of neuropsychiatric disorders is the required initial step in identifying disease pathways and for validating new pharmacological targets<sup><a href="#ref-1">1</a></sup>. A more complete understanding of the disease pathways will facilitate both the selection of therapeutic targets and the development of relevant models for screening drug candidates<sup><a href="#ref-2">2</a></sup>. The pathology-to-drug discovery approach inspired the creation of NEWMEDS (Novel Methods Leading to New Medications in Depression and Schizophrenia), a European project designed to identify specific brain circuits, particularly those involving the prefrontal cortex, that are involved in the pathophysiology and treatment of major depression and schizophrenia<sup><a href="#ref-3">3</a></sup>. On the other hand, a better knowledge of the mechanism of action of older drugs (the so-called reverse translation approach) has permitted, in part, a better understanding of the pathophysiology of neuropsychiatric diseases, enabling drug design according to the pathology-to-drug discovery approach.</p><p class="" id=d9379e235>As the neuropsychopharmacology community has only recently adopted the pathology-to-drug discovery approach, it remains unknown whether agents discovered in this way are currently available for the clinical management of psychiatric disorders and whether such drugs display significant advantages over conventional therapies with respect to efficacy and tolerability.</p><p class="" id=d9379e238>Summarized below are some of the more exciting and relevant advances in the field of neuropsychopharmacology as they pertain to the design and development of novel psychotherapeutics. Highlighted are molecules displaying novel mechanisms of action that were recently approved for human use or that are now undergoing phase II/III clinical trials. Particular emphasis is placed on the identification of new drugs and drug candidates for the treatment of schizophrenia and major depression. Finally, a specific section is dedicated to neurodegenerative disorders such as Alzheimer’s disease (AD), where pharmacological strategies can significantly differ from the approaches currently adopted in psychotic and affective disorders.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e244>Schizophrenia</h2><p class="" id=d9379e247>At a mechanistic level, drug treatments for schizophrenia are presently based on the dopamine hypothesis concerning the symptoms of this disorder<sup><a href="#ref-4">4</a></sup>. The development of second-generation antipsychotics that began 25 years ago has yielded some advances in terms of efficacy, with some modest improvement in addressing the negative symptoms of this condition, and in tolerability, particularly with regard to extrapyramidal side effects<sup><a href="#ref-5">5</a></sup>. However, no antipsychotics display robust effects on the cognitive deficits or impaired social processing that are important components of this disorder<sup><a href="#ref-4">4</a></sup>. For years, the limited efficacy of conventional and second-generation agents has led to theories about whether the manipulation of brain targets other than, or in addition to, the dopamine D2 receptor (D2R) may be necessary for treating this disorder and to significantly improve safety and tolerability.</p><p class="" id=d9379e262>In recent years, the N-methyl-D-aspartate (NMDA) receptor hypothesis of schizophrenia has been validated in preclinical animal models and humans<sup><a href="#ref-6">6</a></sup>. According to this theory, the excessive dopamine release in the mesolimbic pathway and the decrease in dopamine release from the mesocortical pathway in the prefrontal cortex, which are responsible for some of the symptoms of schizophrenia, are secondary to a decrease in NMDA receptor control of inhibitory GABAergic neurons. No drugs capable of selectively enhancing NMDA receptor activity in this key brain region have yet been approved for human use. Studies indicate that prodromal and early-in-disease schizophrenic patients have elevated brain glutamate levels compared to healthy controls and ultra-high-risk patients who do not become psychotic<sup><a href="#ref-7">7</a></sup>. Alterations in NMDA receptor-mediated excitation of GABAergic neurons indicate that schizophrenia is associated with dysfunctional glutamatergic systems in the prefrontal cortex and limbic regions of the brain. One approach has been to target the glutamatergic system using pomaglumetad methionil, a potent and highly selective orthosteric metabotropic glutamate receptor (mGluR) 2/3 agonist<sup><a href="#ref-8">8</a></sup>, but alternative approaches directed at group III mGluRs are also currently studied in preclinical models of schizophrenia<sup><a href="#ref-9">9</a></sup>. Preclinical research suggests that by reducing glutamate release, pomaglumetad methionil normalizes heightened glutamate activity in cortical pyramidal neurons<sup><a href="#ref-8">8</a></sup>. While pomaglumetad methionil was reported to display beneficial effects on both the positive and the negative symptoms of schizophrenia in initial clinical trials, positive results were not obtained in phase III studies. Analysis of the clinical data suggests that pomaglumetad methionil is most efficacious in early-in-disease schizophrenics (&lt;3 years’ duration) with a known hyperactive glutamatergic pathophysiology<sup><a href="#ref-8">8</a></sup>. It is anticipated, therefore, that new antipsychotics acting on the mGluR2/3 will be developed to treat schizophrenic patients in an early phase of the illness with the hope of slowing disease progression and improving prognosis.</p><p class="" id=d9379e290>The dopamine D3 receptor (D3R) is another pharmacological target that appears to play a prominent role in the pathogenesis of schizophrenia. Unlike the D2R, which has been extensively studied with respect to the symptoms of schizophrenia, little is known about the extent to which changes in D3R and dopamine D4 receptor (D4R) activity contribute to the symptoms of this disorder. It is known that the molecular structure of D3R is very similar to that of D2R and D4R and that in a variety of animal species D2R and D3R share high homology<sup><a href="#ref-10">10</a></sup> and identity in the transmembrane regions, including the binding site<sup><a href="#ref-11">11</a></sup>. Such structural similarities make it difficult to design ligands that selectively interact with D3R. This, in turn, has compromised the ability to fully define the localization and functions of this site. A number of approved drugs that were believed to act primarily at the D2R recognition site have now been found to interact with the D3R as well (see <a href="#ref-12">12</a> for review). Cariprazine is the first example of a D3R partial agonist that occupies this receptor at doses that produce antipsychotic-like effects in preclinical animal models<sup><a href="#ref-13">13</a>,<a href="#ref-14">14</a></sup>. Cariprazine displays higher affinity at D3R and a similar affinity at D2 and serotonin 2B (5-HT<sub>2B</sub>) receptors<sup><a href="#ref-13">13</a></sup>. In rodents, cariprazine reverses the deficit in novel object recognition that is caused by neonatal administration of phencyclidine<sup><a href="#ref-14">14</a></sup> or by subchronic phencyclidine exposure in adults<sup><a href="#ref-15">15</a>,<a href="#ref-16">16</a></sup>. Preclinical and clinical data suggest that by selectively activating D3R, cariprazine may have a positive impact on the cognitive symptoms of schizophrenia. Cariprazine was approved in 2015 by the U.S. Food and Drug Administration for the treatment of schizophrenia<sup><a href="#ref-17">17</a></sup>. Further clinical studies with cariprazine and other antipsychotics selectively targeting D3R will be essential to validate the role of D3R as a new pharmacological target for the treatment of cognitive symptoms in schizophrenia.</p><p class="" id=d9379e334>Another new approach proposed for the treatment of schizophrenia is the development of disease-modifying agents to prevent the full onset of schizophrenia and/or to slow its progression<sup><a href="#ref-4">4</a></sup>. Many questions remain as to whether it will be possible to identify drugs that will directly affect the underlying disease process in a way that would delay or prevent disease progression in schizophrenia.</p><p class="" id=d9379e342>There are also many challenges to consider for designing clinical trials to prove that a given drug candidate can modify the course of this disorder over time. A first step might be to identify young individuals who are at high risk for psychosis. Particular emphasis could be placed on those who are also heavy users of cannabis, as there is an increased risk for schizophrenia in those who abuse highly potent preparations of cannabis (so-called “skunk” variants) containing a high percentage of delta-9-tetrahydrocannabinol (THC) (about 15%) with a scarcity of cannabidiol (CBD 0–1%)<sup><a href="#ref-4">4</a>,<a href="#ref-18">18</a></sup>. As a negative allosteric modulator of the cannabinoid 1 (CB1) receptor, CBD ameliorates the psychotogenic effect of THC and may possess antipsychotic properties<sup><a href="#ref-19">19</a></sup>. Given these findings, the CB1 receptor has been proposed as a new pharmacological target for the treatment of schizophrenia<sup><a href="#ref-6">6</a>,<a href="#ref-19">19</a></sup>. Indeed, there have been reports that 800 to 1,000 mg of cannabidiol per day safely reduces the signs and symptoms of schizophrenia<sup><a href="#ref-19">19</a></sup>. However, uncertainty remains about the mechanism of CBD action. Recently, Seeman reported that CBD, like aripiprazole, is a partial agonist at the D2R<sup><a href="#ref-20">20</a></sup>. Thus, CBD could be the first molecule of a class of antipsychotics that interact with both the CB1 and the D2R. Ideal candidates for clinical trials with such agents would be high-risk individuals to assess whether CBD dampens the acute psychotic symptoms and cognitive deficits associated with schizophrenia. Three different phase II clinical trials are underway to assess the clinical efficacy of cannabidiol monotherapy in newly diagnosed schizophrenic patients and as adjunctive therapy with conventional second-generation antipsychotics (NCT02088060 and NCT02504151).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e374>Depression</h2><p class="" id=d9379e377>While currently available antidepressants, such as selective serotonin reuptake inhibitors (SSRIs) and serotonin and noradrenaline reuptake inhibitors (SNRIs), are effective for most patients, approximately 30% of those with major depressive disorder (MDD) fail to respond to these agents<sup><a href="#ref-2">2</a></sup>. Cognitive dysfunction represents a distinct biological and clinical dimension in MDD<sup><a href="#ref-21">21</a></sup>, with evidence suggesting that the presence of cognitive symptoms in depressed patients can predict a low rate of response to antidepressants and reduced remission rates<sup><a href="#ref-22">22</a>,<a href="#ref-23">23</a></sup>. Multimodal drugs, such as vortioxetine, represent a new class of antidepressants. These agents display multiple molecular mechanisms of action in addition to inhibition of the serotonin transporter<sup><a href="#ref-24">24</a>,<a href="#ref-25">25</a></sup>.</p><p class="" id=d9379e402>Vortioxetine is a multimodal antidepressant that is thought to act by inhibition of transmitter reuptake and interactions with various 5-HT receptor sites. This pharmacodynamic profile is well described in the Neuroscience-Based Nomenclature, a new pharmacologically driven classification of psychotropic drugs that reflects current knowledge about the underlying neurobiological characteristics of the disorder, an understanding of the neurotransmitter/molecule/system being modified (“pharmacological domain”), and the mode/mechanism of drug action<sup><a href="#ref-26">26</a></sup>. Vortioxetine is not the only example of a multimodal antidepressant, with others, such as vilazodone (a serotonin transport inhibitor and a 5-HT<sub>1A</sub> receptor partial agonist), having been approved for the treatment of major depression<sup><a href="#ref-27">27</a>,<a href="#ref-28">28</a></sup>. Other psychotropic drugs developed in the last 30 years can possess a multimodal pharmacodynamic profile (see e.g. trazodone), but the novelty of this approach is to combine multiple pharmacological actions affecting both monoamine targets and other non-monoaminergic systems (e.g. glutamatergic system)<sup><a href="#ref-24">24</a></sup>. The multimodal approach seems to be an interesting approach to target the different biological and clinical dimensions of MDD. Current evidence does not suggest a global greater efficacy of multimodal antidepressants compared to SSRIs or SNRIs but an improved efficacy on specific clinical domains where SSRIs or SNRIs are less effective, as observed with vortioxetine, which displays a specific clinical efficacy in the treatment of cognitive deficits associated with MDD<sup><a href="#ref-25">25</a></sup>.</p><p class="" id=d9379e427>Vortioxetine is a 5-HT<sub>3</sub>, 5-HT<sub>7</sub>, and 5-HT<sub>1D</sub> receptor antagonist, 5-HT<sub>1B</sub> receptor partial agonist, 5-HT<sub>1A</sub> receptor agonist, and an inhibitor of the serotonin transporter<sup><a href="#ref-29">29</a></sup>. It is thought to activate the glutamatergic system in rat frontal cortex by blockade of 5-HT<sub>3</sub> and 5-HT<sub>7</sub> receptors. It is reported that, as compared to fluoxetine, vortioxetine displays a superior efficacy in aged mice as a treatment for visuospatial memory and depression-like behavior<sup><a href="#ref-30">30</a></sup>. The pharmacodynamic profile is consistent with the results of clinical studies indicating that vortioxetine has antidepressant properties as well as positive effects on cognitive function (e.g. memory and executive functioning)<sup><a href="#ref-25">25</a></sup>. The most common side effects associated with this drug are nausea, vomiting, and constipation. Vortioxetine is currently studied as a potential therapeutic alternative for patients who fail to respond to SSRIs or SNRIs<sup><a href="#ref-31">31</a></sup>.</p><p class="" id=d9379e468>Drugs, such as ketamine, that are known to affect descending glutamatergic systems represent a new approach for managing treatment-resistant depression (TRD)<sup><a href="#ref-32">32</a></sup>. Several well-controlled clinical studies indicate that a single ketamine infusion (0.5 mg/kg) induces a rapid, generally transient, antidepressant effect in addition to small, but significant, increases in psychotomimetic and dissociative symptoms<sup><a href="#ref-33">33</a></sup>. The ketamine-induced antidepressant effect occurs within 1 to 2 hours following its intravenous administration and may be sustained for up to 2 weeks<sup><a href="#ref-34">34</a></sup>. This rapid onset of action has stimulated studies to explore the possibility that ketamine may represent a life-saving drug for TRD patients at imminent risk of suicide<sup><a href="#ref-35">35</a></sup>. Twice- and thrice-weekly administration of ketamine at 0.5 mg/kg maintains antidepressant efficacy for over 2 weeks with no signs of tolerance<sup><a href="#ref-36">36</a></sup>.</p><p class="" id=d9379e492>It is believed that by blocking NMDA receptors on GABAergic interneurons, ketamine causes a rapid, but transient, increase in extracellular glutamate in the prefrontal cortex. At the molecular level, the ketamine-induced blockade of NMDA receptors results in inhibition of elongation factor 2 (eF2) kinase, de-phosphorylation of eF2, and a consequent augmentation of brain-derived neurotrophic factor (BDNF) synthesis<sup><a href="#ref-32">32</a></sup>. Preclinical and clinical studies with ketamine have resulted in the identification of new pharmacological targets related to NMDA receptor activation or inhibition, such as the NR2B receptor subunit, and the mammalian target of rapamycin (mTOR), a signaling system that controls synaptic plasticity and appears to be a key element in the antidepressant response to ketamine<sup><a href="#ref-32">32</a></sup>. Recent studies also suggest that the pharmacological profile of ketamine is more complex than being a simple NMDA receptor antagonist because this drug also shows a significant affinity for D2R and opioid receptors as well as for monoamine transporters<sup><a href="#ref-37">37</a></sup>. Further studies are needed to identify all the molecular mechanisms underlying the rapid-acting antidepressant effects of ketamine. Efforts are now directed towards the development of new antidepressants displaying the efficacy and rapid onset of action of ketamine but lacking its psychotomimetic effects<sup><a href="#ref-34">34</a></sup>.</p><p class="" id=d9379e511>Attempts are also underway to exploit the established clinical value of ketamine and its derivatives, such as S(+) ketamine (esketamine), while reducing their side effect potential by administering them intramuscularly or intranasally at doses (e.g. 0.2 mg/kg) lower than those used for the intravenous studies<sup><a href="#ref-38">38</a></sup>. Phase III clinical trials are ongoing to assess the safety and clinical efficacy of intranasal esketamine in patients with TRD (NCT02782104, NCT02133001, and NCT02497287).</p><p class="" id=d9379e518>An alternative approach to target the glutamatergic system in MDD and mimic ketamine’s effects might be the use of mGluR5-selective antagonists or negative allosteric modulators<sup><a href="#ref-39">39</a></sup>. This novel approach stems from the evidence that mGluR5s are functionally involved in the mild modulation of NMDA receptor activity and mGluR5 antagonists exert significant antidepressant effects in animal models of depression by acting as mild NMDA receptor negative modulators<sup><a href="#ref-39">39</a></sup>. Therefore, mGluR5s have been recently considered as a new target of novel antidepressants, and basimglurant, a negative allosteric modulator of mGluR5, is now in clinical development for the treatment of MDD (NCT00809562 and NCT01437657).</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e532>Alzheimer’s disease</h2><p class="" id=d9379e535>AD is a neurodegenerative disorder characterized by memory loss, cognitive decline, and neuropsychiatric symptoms that interfere with normal daily activities<sup><a href="#ref-40">40</a></sup>. This disorder is associated with the presence of senile plaques containing amyloid β (Aβ), intracellular aggregates of tau protein in neurofibrillary tangles, and progressive neuronal loss. The amyloid cascade hypothesis<sup><a href="#ref-41">41</a></sup> posits that overproduction of Aβ, or failure to clear this peptide, causes AD because of the aggregation of monomeric Aβ species into higher-molecular-weight Aβ oligomers that results in neuronal cell loss<sup><a href="#ref-42">42</a></sup>.</p><p class="" id=d9379e550>Current drug therapies for AD treat only the symptoms, such as memory loss, while having no effect on the progression of the disease. Drugs included in this group are cholinesterase inhibitors (donepezil, rivastigmine, and galantamine), which are approved for treating mild to moderate AD, and memantine, an NMDA receptor antagonist, which is used to treat patients with moderate to severe AD.</p><p class="" id=d9379e553>Much effort has been expended in developing disease-modifying drugs for the treatment of this condition. Such agents would be able to slow the progression of the pathological changes and their effects would persist even after terminating treatment<sup><a href="#ref-42">42</a></sup>. To date, this effort has failed to yield any clinically effective drugs. One of the difficulties in testing such compounds has been the lack of reliable biomarkers identifying patients in the early stage of the disease. For this reason, most clinical trials were conducted in patients in advanced stages of the disease after irreversible damage to the brain had already occurred. However, the criteria for the diagnosis of AD, revised in 2011 by the National Institute on Aging and the Alzheimer’s Association workgroup<sup><a href="#ref-43">43</a></sup>, now include biomarkers for identifying AD patients earlier. Such individuals are much better candidates for treatment with disease-modifying drugs<sup><a href="#ref-44">44</a></sup>. The development of these biomarkers increases the likelihood of identifying that cohort of patients that is most likely to respond to disease-modifying drugs.</p><p class="" id=d9379e568>Immunotherapy directed towards Aβ has been considered a promising approach because it would, in theory, decrease the aggregation and brain deposition of Aβ. Tau immunotherapy has also been explored as a possible means for inhibiting disease progression in AD<sup><a href="#ref-45">45</a></sup>. Given problems with vaccines, Aβ passive immunotherapy is currently the most popular approach for developing disease-modifying drugs for the treatment of AD<sup><a href="#ref-42">42</a>,<a href="#ref-46">46</a></sup>.</p><p class="" id=d9379e583>As antibody-based immunotherapy against Aβ has so far failed to yield positive clinical results, questions are being raised about the validity of the amyloid hypothesis of AD. However, it remains unknown whether the clinical failures reported for bapineuzumab, gantenerumab, and solanezumab are due to their inability to reduce the formation of Aβ oligomers or because they were tested in inappropriate populations of AD patients<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. Unfortunately, encouraging preliminary results obtained with solanezumab have not been confirmed in recent phase III clinical trials<sup><a href="#ref-47">47</a>,<a href="#ref-48">48</a></sup>. This drug is, however, still in clinical development in prodromal AD patients (NCT02008357 and NCT02760602).</p><p class="" id=d9379e600>The recent positive results with aducanumab in prodromal and mild AD in a phase Ib trial<sup><a href="#ref-49">49</a>,<a href="#ref-50">50</a></sup> suggest that the amyloid hypothesis is still consistent with the development of new disease-modifying drugs, based on this hypothesis, in the near future. Aducanumab is the first example of an antibody developed by selecting human B-cell clones triggered by neo-epitopes present in soluble oligomers and insoluble fibrils. That is, only the pathogenic forms of Aβ<sup><a href="#ref-49">49</a></sup> are affected without interfering with Aβ monomers that exert a critical role in maintaining neuronal survival, learning, and memory<sup><a href="#ref-50">50</a>,<a href="#ref-51">51</a></sup>. It has been established that aducanumab enters the brain and that 1 year of monthly intravenous infusion reduces brain Aβ in a dose- and time-dependent manner in patients with prodromal or mild AD. The greatest effects are observed at doses of 3 and 10 mg/kg. This effect was accompanied by a slowing of the clinical decline as measured by the Clinical Dementia Rating—Sum of Boxes and Mini Mental State Examination scores. As already observed with solanezumab, amyloid-related imaging abnormalities (ARIA), such as vasogenic edema, indicate a dose-dependent response in AD patients<sup><a href="#ref-49">49</a></sup>. The clinical efficacy of aducanumab must be confirmed in the long-term extension phase of this study as well as in the ongoing phase III clinical trials, which may finally validate the amyloid hypothesis in the field of AD.</p></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e628>Conclusion</h2><p class="" id=d9379e631>As indicated in this report, the pathology-to-drug discovery approach is now being applied for the identification of new drugs for the treatment of psychiatric disorders (<a href="#T1">Table 1</a>). This has been responsible, in part, for the identification of new psychiatric medications with novel mechanisms of action (D3R antagonists, vortioxetine, and esketamine). Secondary prevention strategies with glutamatergic agents (mGluR2/3 agonists) or negative allosteric modulators of CB1 (cannabidiol) are under study for the treatment of schizophrenia. If confirmed in ongoing clinical trials, the early results with aducanumab, a possible disease-modifying agent for AD, suggest that the pathology-to-drug discovery approach may be applicable for designing and developing new medications for the treatment of a host of neuropsychiatric disorders.</p><div class="table-wrap panel clearfix"><a name=T1 class=n-a></a><div class=caption><h3>Table 1. Current status of clinical development of new psychotropic drugs for the treatment of neuropsychiatric disorders.</h3></div><table xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class=article-table frame=below><a name=d9379e648 class=n-a></a><thead><a name=d9379e650 class=n-a></a><tr><a name=d9379e652 class=n-a></a><th align=left colspan=1 rowspan=1 valign=top><a name=d9379e654 class=n-a></a>Drug</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9379e657 class=n-a></a>Indication/field</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9379e660 class=n-a></a>Putative<br class=br>mechanism</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9379e665 class=n-a></a>Phase of<br class=br>study of<br class=br>action</th><th align=left colspan=1 rowspan=1 valign=top><a name=d9379e672 class=n-a></a>Main result<br class=br>and/or status</th></tr></thead><tbody><a name=d9379e679 class=n-a></a><tr><a name=d9379e681 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e683 class=n-a></a>Pomaglumetad</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e686 class=n-a></a>Schizophrenia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e689 class=n-a></a>Agonist on<br class=br>mGlu2/3</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e694 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e697 class=n-a></a>Efficacy only in<br class=br>schizophrenic<br class=br>patients with<br class=br>a duration of<br class=br>illness &lt;3 years</td></tr><tr><a name=d9379e709 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e711 class=n-a></a>Cariprazine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e714 class=n-a></a>Schizophrenia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e717 class=n-a></a>D3/D2/5-HT2B<br class=br>ligand with a<br class=br>preferential affinity<br class=br>for D3R</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e726 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e729 class=n-a></a>Approved</td></tr><tr><a name=d9379e733 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e735 class=n-a></a>Cannabidiol</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e738 class=n-a></a>Schizophrenia</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e741 class=n-a></a>CB1 negative<br class=br>allosteric<br class=br>modulator<br class=br>D2R partial agonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e750 class=n-a></a>II</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e753 class=n-a></a>Ongoing</td></tr><tr><a name=d9379e757 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e759 class=n-a></a>Vortioxetine</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e762 class=n-a></a>Depression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e765 class=n-a></a>Multimodal<br class=br>(5-HT receptor<br class=br>agonist/antagonist<br class=br>reuptake inhibitor)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e774 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e777 class=n-a></a>Approved</td></tr><tr><a name=d9379e781 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e783 class=n-a></a>Vilazodone</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e786 class=n-a></a>Depression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e789 class=n-a></a>Multimodal</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e792 class=n-a></a>Approved</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e795 class=n-a></a>Approved</td></tr><tr><a name=d9379e800 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e802 class=n-a></a>Ketamine<br class=br>(esketamine)</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e807 class=n-a></a>Depression</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e810 class=n-a></a>NMDA antagonist</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e813 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e816 class=n-a></a>Ongoing</td></tr><tr><a name=d9379e820 class=n-a></a><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e822 class=n-a></a>Aducanumab</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e825 class=n-a></a>Alzheimer’s<br class=br>disease</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e830 class=n-a></a>Aβ clearance</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e833 class=n-a></a>III</td><td align=left colspan=1 rowspan=1 valign=top><a name=d9379e836 class=n-a></a>Ongoing</td></tr></tbody></table><div class=table-wrap-foot><div class=footnote><a name=d9379e844 class=n-a></a><p id=d9379e846> 5-HT, serotonin; Aβ, amyloid beta; CB1, cannabinoid 1; D2R, dopamine 2 receptor; D3R, dopamine 3 receptor; mGlu, metabotropic glutamate; NMDA, N-methyl-D-aspartate</p></div></div></div></div><div id=article1-body class=generated-article-body><h2 class=main-title id=d9379e856>Abbreviations</h2><p class="" id=d9379e859>5-HT, serotonin; Aβ, amyloid beta; AD, Alzheimer’s disease; CBD, cannabidiol; CB1 receptor, cannabinoid 1 receptor; D2R, dopamine 2 receptor; D3R, dopamine 3 receptor; D4R, dopamine D4 receptor; eF2, elongation factor; MDD, major depressive disorder; mGluR, metabotropic glutamate receptor; mTOR, mammalian target of rapamycin; NMDA, N-methyl-D-aspartate; SNRI, serotonin and noradrenaline reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor; THC, delta-9-tetrahydrocannabinol; TRD, treatment-resistant depression.</p></div><div id=article1-back class=generated-article-footer><div class=back-section><a name=d9379e1 class=n-a></a><h2 class=main-title id=d9528>Competing interests</h2><p class=metadata-entry><a name=d9379e148 class=n-a></a><p id=d9379e150> The author(s) declare that they have no competing interests.</p></p></div><div class=back-section><a name=d9379e1 class=n-a></a><h2 class=main-title id=d9530>Grant information</h2><p>The author(s) declared that no grants were involved in supporting this work.</p></div><div class=back-section><a name=d9379e866 class=n-a></a><span class="research-layout prime-recommended-wrapper reference-heading"><span class="f1r-icon icon-79_faculty_recommended_badge red vmiddle default-cursor"></span><span class="prime-red big">F1000 recommended</span></span><h2 class=main-title id=d9698>References</h2><div class="section ref-list"><a name=d9379e866 class=n-a></a><ul><li><a name=ref-1 class=n-a></a><span class=label>1. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725456759"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e873 class=n-a></a>Millan MJ, Goodwin GM, Meyer-Lindenberg A, <i> et al.</i>: Learning from the past and looking to the future: Emerging perspectives for improving the treatment of psychiatric disorders. <i>Eur Neuropsychopharmacol.</i> 2015; <b>25</b>(5): 599–656. <a target=xrefwindow id=d9379e884 href="http://www.ncbi.nlm.nih.gov/pubmed/25836356">PubMed Abstract </a> | <a target=xrefwindow id=d9379e887 href="http://dx.doi.org/10.1016/j.euroneuro.2015.01.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725456759">F1000 Recommendation</a></span></li><li><a name=ref-2 class=n-a></a><span class=label>2. </span>&nbsp;<span class=citation><a name=d9379e900 class=n-a></a>Pangalos MN, Schechter LE, Hurko O: Drug development for CNS disorders: strategies for balancing risk and reducing attrition. <i>Nat Rev Drug Discov.</i> 2007; <b>6</b>(7): 521–32. <a target=xrefwindow id=d9379e908 href="http://www.ncbi.nlm.nih.gov/pubmed/17599084">PubMed Abstract </a> | <a target=xrefwindow id=d9379e911 href="http://dx.doi.org/10.1038/nrd2094">Publisher Full Text </a></span></li><li><a name=ref-3 class=n-a></a><span class=label>3. </span>&nbsp;<span class=citation><a name=d9379e920 class=n-a></a>Artigas F, Schenker E, Celada P, <i> et al.</i>: Defining the brain circuits involved in psychiatric disorders: IMI-NEWMEDS. <i>Nat Rev Drug Discov.</i> 2016; <b>16</b>(1): 1–2. <a target=xrefwindow id=d9379e931 href="http://www.ncbi.nlm.nih.gov/pubmed/27811930">PubMed Abstract </a> | <a target=xrefwindow id=d9379e934 href="http://dx.doi.org/10.1038/nrd.2016.205">Publisher Full Text </a></span></li><li><a name=ref-4 class=n-a></a><span class=label>4. </span>&nbsp;<span class=citation><a name=d9379e943 class=n-a></a>Millan MJ, Andrieux A, Bartzokis G, <i> et al.</i>: Altering the course of schizophrenia: progress and perspectives. <i>Nat Rev Drug Discov.</i> 2016; <b>15</b>(7): 485–515. <a target=xrefwindow id=d9379e954 href="http://www.ncbi.nlm.nih.gov/pubmed/26939910">PubMed Abstract </a> | <a target=xrefwindow id=d9379e957 href="http://dx.doi.org/10.1038/nrd.2016.28">Publisher Full Text </a></span></li><li><a name=ref-5 class=n-a></a><span class=label>5. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726119631"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e966 class=n-a></a>Garay RP, Citrome L, Samalin L, <i> et al.</i>: Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. <i>Expert Opin Pharmacother.</i> 2016; <b>17</b>(7): 921–36. <a target=xrefwindow id=d9379e977 href="http://www.ncbi.nlm.nih.gov/pubmed/26831200">PubMed Abstract </a> | <a target=xrefwindow id=d9379e980 href="http://dx.doi.org/10.1517/14656566.2016.1149164">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726119631">F1000 Recommendation</a></span></li><li><a name=ref-6 class=n-a></a><span class=label>6. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725313093"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e994 class=n-a></a>Howes O, McCutcheon R, Stone J: Glutamate and dopamine in schizophrenia: an update for the 21<sup>st</sup> century. <i>J Psychopharmacol.</i> 2015; <b>29</b>(2): 97–115. <a target=xrefwindow id=d9379e1005 href="http://www.ncbi.nlm.nih.gov/pubmed/25586400">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1008 href="http://dx.doi.org/10.1177/0269881114563634">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1012 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4902122">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725313093">F1000 Recommendation</a></span></li><li><a name=ref-7 class=n-a></a><span class=label>7. </span>&nbsp;<span class=citation><a name=d9379e1025 class=n-a></a>de la Fuente-Sandoval C, Léon-Ortiz P, Favila R, <i> et al.</i>: Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis. <i>Neuropsychopharmacology.</i> 2011; <b>36</b>(9): 1781–1791. <a target=xrefwindow id=d9379e1036 href="http://www.ncbi.nlm.nih.gov/pubmed/21508933">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1039 href="http://dx.doi.org/10.1038/npp.2011.65">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1043 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3154101">Free Full Text </a></span></li><li><a name=ref-8 class=n-a></a><span class=label>8. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725972312"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1052 class=n-a></a>Kinon BJ, Millen BA, Zhang L, <i> et al.</i>: Exploratory analysis for a targeted patient population responsive to the metabotropic glutamate 2/3 receptor agonist pomaglumetad methionil in schizophrenia. <i>Biol Psychiatry.</i> 2015; <b>78</b>(11): 754–62. <a target=xrefwindow id=d9379e1063 href="http://www.ncbi.nlm.nih.gov/pubmed/25890643">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1066 href="http://dx.doi.org/10.1016/j.biopsych.2015.03.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725972312">F1000 Recommendation</a></span></li><li><a name=ref-9 class=n-a></a><span class=label>9. </span>&nbsp;<span class=citation><a name=d9379e1079 class=n-a></a>Wierońska JM, Acher FC, Sławińska A, <i> et al.</i>: The antipsychotic-like effects of the mGlu group III orthosteric agonist, LSP1-2111, involves 5-HT<sub>1A</sub> signalling. <i>Psychopharmacology (Berl).</i> 2013; <b>227</b>(4): 711–25. <a target=xrefwindow id=d9379e1093 href="http://www.ncbi.nlm.nih.gov/pubmed/23474845">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1097 href="http://dx.doi.org/10.1007/s00213-013-3005-0">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1100 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3663209">Free Full Text </a></span></li><li><a name=ref-10 class=n-a></a><span class=label>10. </span>&nbsp;<span class=citation><a name=d9379e1109 class=n-a></a>Sibley DR, Monsma FJ Jr: Molecular biology of dopamine receptors. <i>Trends Pharmacol Sci.</i> 1992; <b>13</b>(2): 61–69. <a target=xrefwindow id=d9379e1117 href="http://www.ncbi.nlm.nih.gov/pubmed/1561715">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1120 href="http://dx.doi.org/10.1016/0165-6147(92)90025-2">Publisher Full Text </a></span></li><li><a name=ref-11 class=n-a></a><span class=label>11. </span>&nbsp;<span class=citation><a name=d9379e1129 class=n-a></a>Shi L, Javitch JA: The binding site of aminergic G protein-coupled receptors: the transmembrane segments and second extracellular loop. <i>Annu Rev Pharmacol Toxicol.</i> 2002; <b>42</b>: 437–467. <a target=xrefwindow id=d9379e1137 href="http://www.ncbi.nlm.nih.gov/pubmed/11807179">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1140 href="http://dx.doi.org/10.1146/annurev.pharmtox.42.091101.144224">Publisher Full Text </a></span></li><li><a name=ref-12 class=n-a></a><span class=label>12. </span>&nbsp;<span class=citation><a name=d9379e1150 class=n-a></a>Leggio GM, Bucolo C, Platania CB, <i> et al.</i>: Current drug treatments targeting dopamine D3 receptor. <i>Pharmacol Ther.</i> 2016; <b>165</b>: 164–77. <a target=xrefwindow id=d9379e1161 href="http://www.ncbi.nlm.nih.gov/pubmed/27343365">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1164 href="http://dx.doi.org/10.1016/j.pharmthera.2016.06.007">Publisher Full Text </a></span></li><li><a name=ref-13 class=n-a></a><span class=label>13. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/727306452"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1173 class=n-a></a>De Deurwaerdère P: Cariprazine:New dopamine biased agonist for neuropsychiatric disorders. <i>Drugs Today (Barc).</i> 2016; <b>52</b>(2): 97–110. <a target=xrefwindow id=d9379e1181 href="http://www.ncbi.nlm.nih.gov/pubmed/27092339">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1184 href="http://dx.doi.org/10.1358/dot.2016.52.2.2461868">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/727306452">F1000 Recommendation</a></span></li><li><a name=ref-14 class=n-a></a><span class=label>14. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726076038"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1197 class=n-a></a>Watson DJ, King MV, Gyertyán I, <i> et al.</i>: The dopamine D<sub>3</sub>-preferring D<sub>2</sub>/D<sub>3</sub> dopamine receptor partial agonist, cariprazine, reverses behavioural changes in a rat neurodevelopmental model for schizophrenia. <i>Eur Neuropsychopharmacol.</i> 2016; <b>26</b>(2): 208–224. <a target=xrefwindow id=d9379e1218 href="http://www.ncbi.nlm.nih.gov/pubmed/26723167">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1221 href="http://dx.doi.org/10.1016/j.euroneuro.2015.12.020">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726076038">F1000 Recommendation</a></span></li><li><a name=ref-15 class=n-a></a><span class=label>15. </span>&nbsp;<span class=citation><a name=d9379e1234 class=n-a></a>Nagai T, Murai R, Matsui K, <i> et al.</i>: Aripiprazole ameliorates phencyclidine-induced impairment of recognition memory through dopamine D<sub>1</sub> and serotonin 5-HT<sub>1A</sub> receptors. <i>Psychopharmacology (Berl).</i> 2009; <b>202</b>(1–3): 315–328. <a target=xrefwindow id=d9379e1252 href="http://www.ncbi.nlm.nih.gov/pubmed/18679658">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1255 href="http://dx.doi.org/10.1007/s00213-008-1240-6">Publisher Full Text </a></span></li><li><a name=ref-16 class=n-a></a><span class=label>16. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726018727"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1264 class=n-a></a>Neill JC, Grayson B, Kiss B, <i> et al.</i>: Effects of cariprazine, a novel antipsychotic, on cognitive deficit and negative symptoms in a rodent model of schizophrenia symptomatology. <i>Eur Neuropsychopharmacol.</i> 2016; <b>26</b>(1): 3–14. <a target=xrefwindow id=d9379e1275 href="http://www.ncbi.nlm.nih.gov/pubmed/26655189">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1278 href="http://dx.doi.org/10.1016/j.euroneuro.2015.11.016">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726018727">F1000 Recommendation</a></span></li><li><a name=ref-17 class=n-a></a><span class=label>17. </span>&nbsp;<span class=citation><a name=d9379e1291 class=n-a></a>Citrome L: Cariprazine for the Treatment of Schizophrenia: A Review of this Dopamine D3-Preferring D3/D2 Receptor Partial Agonist. <i>Clin Schizophr Relat Psychoses.</i> 2016; <b>10</b>(2): 109–19. <a target=xrefwindow id=d9379e1299 href="http://www.ncbi.nlm.nih.gov/pubmed/27440212">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1302 href="http://dx.doi.org/10.3371/1935-1232-10.2.109">Publisher Full Text </a></span></li><li><a name=ref-18 class=n-a></a><span class=label>18. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725383593"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1312 class=n-a></a>Di Forti M, Marconi A, Carra E, <i> et al.</i>: Proportion of patients in south London with first-episode psychosis attributable to use of high potency cannabis: a case-control study. <i>Lancet Psychiatry.</i> 2015; <b>2</b>(3): 233–8. <a target=xrefwindow id=d9379e1323 href="http://www.ncbi.nlm.nih.gov/pubmed/26359901">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1326 href="http://dx.doi.org/10.1016/S2215-0366(14)00117-5">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725383593">F1000 Recommendation</a></span></li><li><a name=ref-19 class=n-a></a><span class=label>19. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726136838"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1339 class=n-a></a>Leweke FM, Mueller JK, Lange B, <i> et al.</i>: Therapeutic Potential of Cannabinoids in Psychosis. <i>Biol Psychiatry.</i> 2016; <b>79</b>(7): 604–12. <a target=xrefwindow id=d9379e1350 href="http://www.ncbi.nlm.nih.gov/pubmed/26852073">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1353 href="http://dx.doi.org/10.1016/j.biopsych.2015.11.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726136838">F1000 Recommendation</a></span></li><li><a name=ref-20 class=n-a></a><span class=label>20. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726858928"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1366 class=n-a></a>Seeman P: Cannabidiol is a partial agonist at dopamine D2High receptors, predicting its antipsychotic clinical dose. <i>Transl Psychiatry.</i> 2016; <b>6</b>(10): e920. <a target=xrefwindow id=d9379e1374 href="http://www.ncbi.nlm.nih.gov/pubmed/27754480">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1377 href="http://dx.doi.org/10.1038/tp.2016.195">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1380 href="http://www.ncbi.nlm.nih.gov/pmc/articles/5315552">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726858928">F1000 Recommendation</a></span></li><li><a name=ref-21 class=n-a></a><span class=label>21. </span>&nbsp;<span class=citation><a name=d9379e1393 class=n-a></a>McIntyre RS, Cha DS, Soczynska JK, <i> et al.</i>: Cognitive deficits and functional outcomes in major depressive disorder: determinants, substrates, and treatment interventions. <i>Depress Anxiety.</i> 2013; <b>30</b>(6): 515–27. <a target=xrefwindow id=d9379e1404 href="http://www.ncbi.nlm.nih.gov/pubmed/23468126">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1407 href="http://dx.doi.org/10.1002/da.22063">Publisher Full Text </a></span></li><li><a name=ref-22 class=n-a></a><span class=label>22. </span>&nbsp;<span class=citation><a name=d9379e1416 class=n-a></a>Castellano S, Ventimiglia A, Salomone S, <i> et al.</i>: Selective Serotonin Reuptake Inhibitors and Serotonin and Noradrenaline Reuptake Inhibitors Improve Cognitive Function in Partial Responders Depressed Patients: Results from a Prospective Observational Cohort Study. <i>CNS Neurol Disord Drug Targets.</i> 2016; <b>15</b>(10): 1290–1298. <a target=xrefwindow id=d9379e1427 href="http://www.ncbi.nlm.nih.gov/pubmed/27712575">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1430 href="http://dx.doi.org/10.2174/1871527315666161003170312">Publisher Full Text </a></span></li><li><a name=ref-23 class=n-a></a><span class=label>23. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/720608758"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1439 class=n-a></a>Roca M, Monzón S, Vives M, <i> et al.</i>: Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study. <i>J Affect Disor.</i> 2015; <b>171</b>: 85–92. <a target=xrefwindow id=d9379e1450 href="http://www.ncbi.nlm.nih.gov/pubmed/25299439">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1453 href="http://dx.doi.org/10.1016/j.jad.2014.09.018">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/720608758">F1000 Recommendation</a></span></li><li><a name=ref-24 class=n-a></a><span class=label>24. </span>&nbsp;<span class=citation><a name=d9379e1467 class=n-a></a>Richelson E: Multi-modality: a new approach for the treatment of major depressive disorder. <i>Int J Neuropsychopharmacol.</i> 2013; <b>16</b>(6): 1433–1442. <a target=xrefwindow id=d9379e1475 href="http://www.ncbi.nlm.nih.gov/pubmed/23363735">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1478 href="http://dx.doi.org/10.1017/S1461145712001605">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1481 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3670520">Free Full Text </a></span></li><li><a name=ref-25 class=n-a></a><span class=label>25. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726352410"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1490 class=n-a></a>Thase ME, Mahableshwarkar AR, Dragheim M, <i> et al.</i>: A meta-analysis of randomized, placebo-controlled trials of vortioxetine for the treatment of major depressive disorder in adults. <i>Eur Neuropsychopharmacol.</i> 2016; <b>26</b>(6): 979–93. <a target=xrefwindow id=d9379e1501 href="http://www.ncbi.nlm.nih.gov/pubmed/27139079">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1504 href="http://dx.doi.org/10.1016/j.euroneuro.2016.03.007">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726352410">F1000 Recommendation</a></span></li><li><a name=ref-26 class=n-a></a><span class=label>26. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726015295"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1517 class=n-a></a>Zohar J, Stahl S, Moller HJ, <i> et al.</i>: A review of the current nomenclature for psychotropic agents and an introduction to the Neuroscience-based Nomenclature. <i>Eur Neuropsychopharmacol.</i> 2015; <b>25</b>(12): 2318–2325. <a target=xrefwindow id=d9379e1528 href="http://www.ncbi.nlm.nih.gov/pubmed/26527055">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1531 href="http://dx.doi.org/10.1016/j.euroneuro.2015.08.019">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726015295">F1000 Recommendation</a></span></li><li><a name=ref-27 class=n-a></a><span class=label>27. </span>&nbsp;<span class=citation><a name=d9379e1544 class=n-a></a>Wang SM, Han C, Lee SJ, <i> et al.</i>: Vilazodone for the treatment of major depressive disorder: focusing on its clinical studies and mechanism of action. <i>Psychiatry Investig.</i> 2015; <b>12</b>(2): 155–63. <a target=xrefwindow id=d9379e1555 href="http://www.ncbi.nlm.nih.gov/pubmed/25866514">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1558 href="http://dx.doi.org/10.4306/pi.2015.12.2.155">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1562 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4390584">Free Full Text </a></span></li><li><a name=ref-28 class=n-a></a><span class=label>28. </span>&nbsp;<span class=citation><a name=d9379e1571 class=n-a></a>Al-Sukhni M, Maruschak NA, McIntyre RS: Vortioxetine : a review of efficacy, safety and tolerability with a focus on cognitive symptoms in major depressive disorder. <i>Expert Opin Drug Saf.</i> 2015; <b>14</b>(8): 1291–304. <a target=xrefwindow id=d9379e1579 href="http://www.ncbi.nlm.nih.gov/pubmed/26022537">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1582 href="http://dx.doi.org/10.1517/14740338.2015.1046836">Publisher Full Text </a></span></li><li><a name=ref-29 class=n-a></a><span class=label>29. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718489555"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1591 class=n-a></a>Sanchez C, Asin KE, Artigas F: Vortioxetine, a novel antidepressant with multimodal activity: Review of preclinical and clinical data. <i>Pharmacol Ther.</i> 2015; <b>145</b>: 43–57. <a target=xrefwindow id=d9379e1599 href="http://www.ncbi.nlm.nih.gov/pubmed/25016186">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1602 href="http://dx.doi.org/10.1016/j.pharmthera.2014.07.001">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718489555">F1000 Recommendation</a></span></li><li><a name=ref-30 class=n-a></a><span class=label>30. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725560473"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1616 class=n-a></a>Li Y, Abdourahman A, Tamm JA, <i> et al.</i>: Reversal of age-associated cognitive deficits is accompanied by increased plasticity-related gene expression after chronic antidepressant administration in middle-aged mice. <i>Pharmacol Biochem Behav.</i> 2015; <b>135</b>: 70–82. <a target=xrefwindow id=d9379e1627 href="http://www.ncbi.nlm.nih.gov/pubmed/26046533">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1630 href="http://dx.doi.org/10.1016/j.pbb.2015.05.013">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725560473">F1000 Recommendation</a></span></li><li><a name=ref-31 class=n-a></a><span class=label>31. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725990331"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1643 class=n-a></a>Brignone M, Diamand F, Painchault C, <i> et al.</i>: Efficacy and tolerability of switching therapy to vortioxetine versus other antidepressants in patients with major depressive disorder. <i>Curr Med Res Opin.</i> 2016; <b>32</b>(2): 351–66. <a target=xrefwindow id=d9379e1654 href="http://www.ncbi.nlm.nih.gov/pubmed/26637048">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1657 href="http://dx.doi.org/10.1185/03007995.2015.1128404">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725990331">F1000 Recommendation</a></span></li><li><a name=ref-32 class=n-a></a><span class=label>32. </span>&nbsp;<span class=citation><a name=d9379e1670 class=n-a></a>Duman RS: Neurobiological advances identify novel antidepressant targets. <i>World Psychiatry.</i> 2013; <b>12</b>(3): 207–9. <a target=xrefwindow id=d9379e1678 href="http://www.ncbi.nlm.nih.gov/pubmed/24096777">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1681 href="http://dx.doi.org/10.1002/wps.20058">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1684 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3799242">Free Full Text </a></span></li><li><a name=ref-33 class=n-a></a><span class=label>33. </span>&nbsp;<span class=citation><a name=d9379e1693 class=n-a></a>Rasmussen KG: Has psychiatry tamed the "ketamine tiger?" Considerations on its use for depression and anxiety. <i>Prog Neuropsychopharmacol Biol Psychiatry.</i> 2016; <b>64</b>: 218–24. <a target=xrefwindow id=d9379e1701 href="http://www.ncbi.nlm.nih.gov/pubmed/25582770">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1704 href="http://dx.doi.org/10.1016/j.pnpbp.2015.01.002">Publisher Full Text </a></span></li><li><a name=ref-34 class=n-a></a><span class=label>34. </span>&nbsp;<span class=citation><a name=d9379e1713 class=n-a></a>Sanacora G, Schatzberg AF: Ketamine: promising path or false prophecy in the development of novel therapeutics for mood disorders? <i>Neuropsychopharmacology.</i> 2015; <b>40</b>(2): 259–67. <a target=xrefwindow id=d9379e1721 href="http://www.ncbi.nlm.nih.gov/pubmed/25257213">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1724 href="http://dx.doi.org/10.1038/npp.2014.261">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1727 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4443967">Free Full Text </a></span></li><li><a name=ref-35 class=n-a></a><span class=label>35. </span>&nbsp;<span class=citation><a name=d9379e1736 class=n-a></a>Bobo WV, Voort JL, Croarkin PE, <i> et al.</i>: Ketamine For Treatment-Resistant Unipolar And Bipolar Major Depression: Critical Review And Implications For Clinical Practice. <i>Depress Anxiety.</i> 2016; <b>33</b>(8): 698–710. <a target=xrefwindow id=d9379e1747 href="http://www.ncbi.nlm.nih.gov/pubmed/27062450">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1750 href="http://dx.doi.org/10.1002/da.22505">Publisher Full Text </a></span></li><li><a name=ref-36 class=n-a></a><span class=label>36. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726273348"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1760 class=n-a></a>Singh JB, Fedgchin M, Daly EJ, <i> et al.</i>: A Double-Blind, Randomized, Placebo-Controlled, Dose-Frequency Study of Intravenous Ketamine in Patients With Treatment-Resistant Depression. <i>Am J Psychiatry.</i> 2016; <b>173</b>(8): 816–26. <a target=xrefwindow id=d9379e1771 href="http://www.ncbi.nlm.nih.gov/pubmed/27056608">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1774 href="http://dx.doi.org/10.1176/appi.ajp.2016.16010037">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726273348">F1000 Recommendation</a></span></li><li><a name=ref-37 class=n-a></a><span class=label>37. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726361401"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1787 class=n-a></a>Ficek J, Zygmunt M, Piechota M, <i> et al.</i>: Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. <i>BMC Genomics.</i> 2016; <b>17</b>: 362. <a target=xrefwindow id=d9379e1798 href="http://www.ncbi.nlm.nih.gov/pubmed/27188165">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1801 href="http://dx.doi.org/10.1186/s12864-016-2713-3">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1805 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4869301">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726361401">F1000 Recommendation</a></span></li><li><a name=ref-38 class=n-a></a><span class=label>38. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/718367177"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1818 class=n-a></a>Lapidus KA, Levitch CF, Perez AM, <i> et al.</i>: A randomized controlled trial of intranasal ketamine in major depressive disorder. <i>Biol Psychiatry.</i> 2014; <b>76</b>(12): 970–6. <a target=xrefwindow id=d9379e1829 href="http://www.ncbi.nlm.nih.gov/pubmed/24821196">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1832 href="http://dx.doi.org/10.1016/j.biopsych.2014.03.026">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1836 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4185009">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/718367177">F1000 Recommendation</a></span></li><li><a name=ref-39 class=n-a></a><span class=label>39. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726506847"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1849 class=n-a></a>Pałucha-Poniewiera A, Pilc A: Glutamate-Based Drug Discovery for Novel Antidepressants. <i>Expert Opin Drug Discov.</i> 2016; <b>11</b>(9): 873–83. <a target=xrefwindow id=d9379e1857 href="http://www.ncbi.nlm.nih.gov/pubmed/27409299">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1860 href="http://dx.doi.org/10.1080/17460441.2016.1213234">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726506847">F1000 Recommendation</a></span></li><li><a name=ref-40 class=n-a></a><span class=label>40. </span>&nbsp;<span class=citation><a name=d9379e1873 class=n-a></a>Ballard CG, Gauthier S, Cummings JL, <i> et al.</i>: Management of agitation and aggression associated with Alzheimer disease. <i>Nat Rev Neurol.</i> 2009; <b>5</b>(5): 245–55. <a target=xrefwindow id=d9379e1884 href="http://www.ncbi.nlm.nih.gov/pubmed/19488082">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1887 href="http://dx.doi.org/10.1038/nrneurol.2009.39">Publisher Full Text </a></span></li><li><a name=ref-41 class=n-a></a><span class=label>41. </span>&nbsp;<span class=citation><a name=d9379e1896 class=n-a></a>Selkoe DJ, Hardy J: The amyloid hypothesis of Alzheimer's disease at 25 years. <i>EMBO Mol Med.</i> 2016; <b>8</b>(6): 595–608. <a target=xrefwindow id=d9379e1904 href="http://www.ncbi.nlm.nih.gov/pubmed/27025652">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1907 href="http://dx.doi.org/10.15252/emmm.201606210">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1910 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4888851">Free Full Text </a></span></li><li><a name=ref-42 class=n-a></a><span class=label>42. </span>&nbsp;<span class=citation><a name=d9379e1920 class=n-a></a>Salomone S, Caraci F, Leggio GM, <i> et al.</i>: New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. <i>Br J ClinPharmacol.</i> 2012; <b>73</b>(4): 504–17. <a target=xrefwindow id=d9379e1931 href="http://www.ncbi.nlm.nih.gov/pubmed/22035455">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1934 href="http://dx.doi.org/10.1111/j.1365-2125.2011.04134.x">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1938 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3376428">Free Full Text </a></span></li><li><a name=ref-43 class=n-a></a><span class=label>43. </span>&nbsp;<span class=citation><a name=d9379e1947 class=n-a></a>Albert MS, DeKosky ST, Dickson D, <i> et al.</i>: The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. <i>Alzheimers Dement.</i> 2011; <b>7</b>(3): 270–9. <a target=xrefwindow id=d9379e1958 href="http://www.ncbi.nlm.nih.gov/pubmed/21514249">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1961 href="http://dx.doi.org/10.1016/j.jalz.2011.03.008">Publisher Full Text </a> | <a target=xrefwindow id=d9379e1965 href="http://www.ncbi.nlm.nih.gov/pmc/articles/3312027">Free Full Text </a></span></li><li><a name=ref-44 class=n-a></a><span class=label>44. </span>&nbsp;<span class=citation><a name=d9379e1974 class=n-a></a>Caraci F, Castellano S, Salomone S, <i> et al.</i>: Searching for disease-modifying drugs in AD: can we combine neuropsychological tools with biological markers? <i>CNS Neurol Disord Drug Targets.</i> 2014; <b>13</b>(1): 173–86. <a target=xrefwindow id=d9379e1985 href="http://www.ncbi.nlm.nih.gov/pubmed/24040795">PubMed Abstract </a> | <a target=xrefwindow id=d9379e1988 href="http://dx.doi.org/10.2174/18715273113129990103">Publisher Full Text </a></span></li><li><a name=ref-45 class=n-a></a><span class=label>45. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725927298"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e1997 class=n-a></a>Sigurdsson EM: Tau Immunotherapy. <i>Neurodegener Dis.</i> 2016; <b>16</b>(1–2): 34–8. <a target=xrefwindow id=d9379e2005 href="http://www.ncbi.nlm.nih.gov/pubmed/26551002">PubMed Abstract </a> | <a target=xrefwindow id=d9379e2008 href="http://dx.doi.org/10.1159/000440842">Publisher Full Text </a> | <a target=xrefwindow id=d9379e2011 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4777344">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725927298">F1000 Recommendation</a></span></li><li><a name=ref-46 class=n-a></a><span class=label>46. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/725393996"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e2024 class=n-a></a>Wisniewski T, Goñi F: Immunotherapeutic approaches for Alzheimer's disease. <i>Neuron.</i> 2015; <b>85</b>(6): 1162–76. <a target=xrefwindow id=d9379e2032 href="http://www.ncbi.nlm.nih.gov/pubmed/25789753">PubMed Abstract </a> | <a target=xrefwindow id=d9379e2035 href="http://dx.doi.org/10.1016/j.neuron.2014.12.064">Publisher Full Text </a> | <a target=xrefwindow id=d9379e2038 href="http://www.ncbi.nlm.nih.gov/pmc/articles/4366618">Free Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/725393996">F1000 Recommendation</a></span></li><li><a name=ref-47 class=n-a></a><span class=label>47. </span>&nbsp;<span class=citation><a name=d9379e2051 class=n-a></a>Shifu X: F1000Prime Recommendation of [Doody RS et al., N Engl J Med 2014, 370(4): 311–21]. In <i>F1000Prime.</i> 2014. <a target=xrefwindow id=d9379e2056 href="http://dx.doi.org/10.3410/f.718248469.793494011">Publisher Full Text </a></span></li><li><a name=ref-48 class=n-a></a><span class=label>48. </span>&nbsp;<span class=citation><a name=d9379e2066 class=n-a></a>Siemers ER, Sundell KL, Carlson C, <i> et al.</i>: Phase 3 solanezumab trials: Secondary outcomes in mild Alzheimer's disease patients. <i>Alzheimers Dement.</i> 2016; <b>12</b>(2): 110–20. <a target=xrefwindow id=d9379e2077 href="http://www.ncbi.nlm.nih.gov/pubmed/26238576">PubMed Abstract </a> | <a target=xrefwindow id=d9379e2080 href="http://dx.doi.org/10.1016/j.jalz.2015.06.1893">Publisher Full Text </a></span></li><li><a name=ref-49 class=n-a></a><span class=label>49. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726696119"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e2089 class=n-a></a>Sevigny J, Chiao P, Bussière T, <i> et al.</i>: The antibody aducanumab reduces Aβ plaques in Alzheimer's disease. <i>Nature.</i> 2016; <b>537</b>(7618): 50–6. <a target=xrefwindow id=d9379e2100 href="http://www.ncbi.nlm.nih.gov/pubmed/27582220">PubMed Abstract </a> | <a target=xrefwindow id=d9379e2103 href="http://dx.doi.org/10.1038/nature19323">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726696119">F1000 Recommendation</a></span></li><li><a name=ref-50 class=n-a></a><span class=label>50. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/1163644"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e2116 class=n-a></a>Giuffrida ML, Caraci F, Pignataro B, <i> et al.</i>: Beta-amyloid monomers are neuroprotective. <i>J Neurosci.</i> 2009; <b>29</b>(34): 10582–10587. <a target=xrefwindow id=d9379e2127 href="http://www.ncbi.nlm.nih.gov/pubmed/19710311">PubMed Abstract </a> | <a target=xrefwindow id=d9379e2130 href="http://dx.doi.org/10.1523/JNEUROSCI.1736-09.2009">Publisher Full Text </a> | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/1163644">F1000 Recommendation</a></span></li><li><a name=ref-51 class=n-a></a><span class=label>51. </span>&nbsp;<span class=citation><a target=_blank title="F1000 recommended" class="research-layout prime-recommended-reference" href="http://f1000.com/prime/726696119"><span class="f1r-icon icon-79_faculty_recommended_badge small red vmiddle"></span></a><a name=d9379e2143 class=n-a></a>F1000Prime Recommendations, Dissents and Comments for [SevignyJ <i>et al.</i>, Nature 2016, 537: 50–6]. In <i>F1000Prime.</i> 2016. | <a target=_blank title="F1000 recommended" href="http://f1000.com/prime/726696119">F1000 Recommendation</a></span></li></ul></div></div></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-397/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-397/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> <div class="f1r-article-mobile margin-bottom-30"> <div class=contracted-details> <a href="#" class="contracted-details-label author-affiliations"><span class=contracted></span>Author details</a> <a href="#" class=section-title>Author details</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details affiliations is-hidden"> <sup>1</sup> Department of Drug Sciences, University of Catania, Catania, Italy<br/> <sup>2</sup> IRCCS Associazione Oasi Maria S.S., Institute for Research on Mental Retardation and Brain Aging, Troina (EN), Italy<br/> <sup>3</sup> Department of Biomedical and Biotechnological Sciences, University of Catania, Catania, Italy<br/> <p> </p> </div> </div> <div class=contracted-details> <a href="#" class=section-title>Article Versions (1)</a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> <div> <a href="https://f1000research.com/articles/6-397/v1" title="Open version 1 of this article." class="" gahelper=1>version 1</a> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div> Published: 30 Mar 2017, 6:397 </div> <div class=""><a href="https://doi.org/10.12688/f1000research.10233.1">https://doi.org/10.12688/f1000research.10233.1</a></div> </div> </div> <div class=contracted-details> <a href="#" class=section-title> <span class="f1r-icon icon-100_open_access"></span> Copyright </a> <span class="f1r-icon icon-14_more_small section-control"></span> <span class="f1r-icon icon-10_less_small section-control"></span> <div class="expanded-details grant-information article-page is-hidden"> © 2017 Caraci F <em>et al</em>. This is an open access article distributed under the terms of the <a href="http://creativecommons.org/licenses/by/4.0/" target=_blank data-test-id=box-licence-link>Creative Commons Attribution License</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. </div> </div> <div class="padding-top-30 research-layout"> <div class=article-toolbox-wrapper-mobile> <div class=article-tools-icon-mobile data-section=download> <span class="f1r-icon icon-76_download_file white"></span> </div> <div class="article-tools-icon-mobile mobile-metrics article-metrics-wrapper metrics-icon-wrapper" data-section=metrics data-version-id=11022 data-id=10233 data-downloads="" data-views="" data-scholar="10.12688/f1000research.10233.1" data-recommended="" data-f1r-ga-helper="Article Page Metrics (Mobile)"> <span class="f1r-icon icon-89_metrics white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=cite> <span class="f1r-icon icon-82_quote white"></span> </div> <div class="article-tools-icon-mobile " data-section=track> <span class="f1r-icon icon-90_track white"></span> </div> <div class=article-tools-divider-mobile></div> <div class=article-tools-icon-mobile data-section=share> <span class="f1r-icon icon-34_share white"></span> </div> <span class=article-toolbox-stretch></span> </div> <div class=article-toolbox-content-mobile> <div class="toolbox-section download"> <div class=toolbox-section-heading>Download</div> <div class=toolbox-section-content> <a href="https://f1000research.com/articles/6-397/v1/pdf?article_uuid=58ff8232-e6ad-4330-a658-d1a5c9b8dcf5" title="Download PDF" class="no-decoration pdf-download-helper"> <span class="f1r-icon icon-102_download_pdf toolbox-section-icon"></span> </a> <div class=toolbox-section-option-divider>&nbsp;</div> <a id=mobile-download-xml class=no-decoration href="#" title="Download XML"> <span class="f1r-icon icon-103_download_xml toolbox-section-icon"></span> </a> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>Export To</div> <div class=toolbox-section-content> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=WORKSPACE>Sciwheel</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=BIBTEX>Bibtex</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=ENDNOTE>EndNote</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=PROCITE>ProCite</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=REF_MANAGER>Ref. Manager (RIS)</button> <button class="primary no-fill orange-text-and-border mobile-export" data-etype=SENTE>Sente</button> </div> </div> <div class="toolbox-section metrics"> <div class="toolbox-section-heading no-top-border">metrics</div> <div class="toolbox-section-divider toolbox-section-divider--no-height"></div> <div class=article-metrics-pageinfo> <div class=c-article-metrics-table> <table class=c-article-metrics-table__table> <thead> <tr> <th></th> <th><span class=c-article-metrics-table__heading>Views</span></th> <th><span class=c-article-metrics-table__heading>Downloads</span></th> </tr> </thead> <tbody> <tr> <th class=c-article-metrics-table__row-heading><span class="c-article-metrics-table__platform u-platform--" data-test-id=metrics_platform_name_mob>F1000Research</span></th> <td class="c-article-metrics-table__value js-article-views-count" data-test-id=metrics_platform_views_mob>-</td> <td class="c-article-metrics-table__value js-article-downloads-count" data-test-id=metrics_platform_downloads_mob>-</td> </tr> <tr> <th class=c-article-metrics-table__row-heading> <span class="u-ib u-middle c-article-metrics-table__pmc" data-test-id=metrics_pmc_name_mob>PubMed Central</span> <div class="c-block-tip c-block-tip--centered c-article-metrics-table__tooltip c-block-tip--md-padding c-block-tip--small-arrow u-ib u-middle"> <button type=button class="u-black--medium u-black--high@hover u-ib u-middle c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content>Data from PMC are received and updated monthly.</div> </div> </th> <td class="c-article-metrics-table__value js-pmc-views-count" data-test-id=metrics_pmc_views_mob>-</td> <td class="c-article-metrics-table__value js-pmc-downloads-count" data-test-id=metrics_pmc_downloads_mob>-</td> </tr> </tbody> </table> </div> </div> <span class=metrics-citations-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-heading u-mb--1">Citations</div> <div> <div class=toolbox-section-colsplit> <div class=citations-scopus-logo> <a href="" target=_blank class="is-hidden metrics-citation-icon" title="View full citation details at www.scopus.com"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count scopus"> <a href='' class='scopus-citation-link is-hidden' target=_blank title='View full citation details at www.scopus.com'>0</a> </div> </div> <div class=toolbox-section-colsplit> <div class="citations-pubmed-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon f1000research" title="View full citation details"><i class="material-icons scopus-icon">open_in_new</i></a> </div> <div class="toolbox-section-count pubmed"> <a href='' class='pubmed-citation-link is-hidden' target=_blank title='View full citation details'>0</a> </div> </div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <div class="citations-scholar-logo f1000research"> <a href="" target=_blank class="is-hidden metrics-citation-icon google-scholar f1000research" title="View full citation details" data-scholar="10.12688/f1000research.10233.1"><i class="material-icons scopus-icon">open_in_new</i></a> </div> </div> </div> </span> <span class=metrics-details-container> <div class=toolbox-section-divider></div> <div class="toolbox-section-content altmetric-section"> <div class=altmetrics-image></div> <div class=altmetrics-more-link> <a href="" target=_blank class=f1r-standard-link>SEE MORE DETAILS</a> </div> <div class=altmetric-mobile-column-counts></div> <div class=altmetric-mobile-column-readers></div> <div class=toolbox-section-divider></div> </div> </span> </div> <div class="toolbox-section cite"> <div class="toolbox-section-heading no-top-border">CITE</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>how to cite this article</div> <div id=citation-copy-mobile class="toolbox-section-content text-content heading9 small" data-test-id=mob_copy-citation_text> Caraci F, Leggio GM, Salomone S and Drago F. New drugs in psychiatry: focus on new pharmacological targets [version 1; peer review: 3 approved] <i>F1000Research</i> 2017, <b>6</b>(F1000 Faculty Rev):397 (<a href="https://doi.org/10.12688/f1000research.10233.1" target=_blank>https://doi.org/10.12688/f1000research.10233.1</a>) </div> <div class=toolbox-section-divider></div> <div class="toolbox-section-content text-content heading9 small"> NOTE: <em>it is important to ensure the information in <b>square brackets after the title</b> is included in all citations of this article.</em> </div> <div class=toolbox-section-content> <button class="primary orange extra-padding copy-cite-article-mobile js-clipboard" data-clipboard-target="#citation-copy-mobile" title="Copy the current citation details." data-test-id=mob_copy-citation_button-mob>COPY CITATION DETAILS</button> </div> </div> <div class="toolbox-section track"> <div class="toolbox-section-heading no-top-border">track</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-heading>receive updates on this article</div> <div class="toolbox-section-content padding-left-20 padding-right-20 heading9 small"> Track an article to receive email alerts on any updates to this article. </div> <div class=toolbox-section-content> <a data-article-id=10233 id=mobile-track-article-signin-10233 title="Receive updates on new activity such as publication of new versions, peer reviews or author responses." href="/login?originalPath=/trackArticle/10233?target=/articles/6-397/v1"> <button class="primary orange extra-padding"> TRACK THIS ARTICLE </button> </a> </div> </div> <div class="toolbox-section share"> <div class="toolbox-section-heading no-top-border">Share</div> <div class=toolbox-section-divider></div> <div class=toolbox-section-content> <a target=_blank class="f1r-shares-icon-square f1r-shares-email" title="Email this article"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-twitter" title="Share on Twitter"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-facebook" title="Share on Facebook"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-linkedin" title="Share on LinkedIn"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-reddit" title="Share on Reddit"></a> <a target=_blank class="f1r-shares-icon-square f1r-shares-mendelay" title="Share on Mendeley"></a> <div class="email-article-wrapper email-article-version-container"> <div class=toolbox-section-divider></div> <script src='https://www.recaptcha.net/recaptcha/api.js'></script> <form class="recommend-version-form-mobile research-layout"> <p>All fields are required.</p> <input name=versionId type=hidden value=11022 /> <input name=articleId type=hidden value=10233 /> <input name=senderName class="form-input-field reg-form" value="" type=text placeholder="Your name"/> <input name=senderEmail class="form-input-field reg-form margin-top" value="" type=text placeholder="Your email address"/> <textarea name=recipientEmails class="form-textarea-field ninetynine-percent-wide margin-top no-resize" placeholder="Recipient email address(es) (comma delimited)"></textarea> <input class="form-input-field reg-form margin-top" name=subject type=text value="Interesting article on F1000Research" placeholder=Subject /> <textarea name=message class="form-textarea-field reg-form margin-top no-resize">I thought this article from F1000Research (https://f1000research.com) would be of interest to you.</textarea> <div class="g-recaptcha margin-top" data-sitekey=6LcHqxoUAAAAANP3_0TzpGG6qFvl4DhbUcuRzw7W></div> <input value="" name=captcha type=hidden /> <p>A full article citation will be automatically included.</p> <p><img class="ticker-email-article-details hidden" src="/img/ticker.gif" alt=loading /></p> <button class="secondary orange margin-bottom" data-test-id=version_share_email_send>SEND EMAIL</button> <div class="orange-message margin-bottom is-hidden" data-test-id=version_share_email_message></div> </form> </div> </div> </div> </div> </div> <a name=article-reports></a> <div id=article-reports class="u-mt--3 reports-comments no-divider"> <div class="current-referee-status current-referee-status--faculty "> <h2 class=main-title id=current-referee-status> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-85_peer_review size30"></span> </span> Open Peer Review <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> <a name=current-referee-status></a> <div class=current-referee-status__content name=add-new-report-comment id=add-new-report-comment> Current Reviewer Status: <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-desk-inline"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile float-right"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> </span> <span class="research-layout f1r-article-mobile"> <div class=mobile-ref-status-help> Key to Reviewer Statuses <span class=referee-status-pointer></span> <span class="view-control float-right">VIEW</span> <span class="view-control float-right is-hidden">HIDE</span> <div class=mobile-ref-status-help-content> <div class="cf margin-top"> <span class="f1r-icon icon-86_approved status-green smaller float-left margin-bottom-40 margin-right" title=Approved></span> <span class=title>Approved</span>The paper is scientifically sound in its current form and only minor, if any, improvements are suggested </div> <div class="cf margin-top"> <span class="f1r-icon icon-87_approved_reservations status-green smaller float-left margin-bottom-40 margin-right" title="Approved with Reservations"></span> <span class=title>Approved with reservations</span> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </div> <div class="cf margin-top"> <span class="f1r-icon icon-88_not_approved status-red small float-left margin-bottom-30 margin-right" title="Not Approved"></span> <span class=title>Not approved</span>Fundamental flaws in the paper seriously undermine the findings and conclusions </div> </div> </div> </span> <div class=editorial-note> <h5 class=editorial-note__title>Editorial Note on the Review Process</h5> <p class=editorial-note__text><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home">Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> </div> <div class=approved-referee> <h4 class=approved-referee__title>Reviewers who approved this article</h4> <ol class=approved-referee__list> <li class="approved-referee__list-item "> <span class=approved-referee__co-referee> <strong>S. J. Enna</strong>, Research and Graduate Education, Department of Physiology and Pharmacology, Kansas University Medical Center, USA </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Philippe De Deurwaerd&egrave;re</strong>, CNRS, Institut des Maladies Neurodégénératives, France </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> <li class="approved-referee__list-item margin-top-20"> <span class=approved-referee__co-referee> <strong>Andrzej Pilc</strong>, Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Poland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> <span class=approved-referee__co-referee> <strong>Michal Korostynski</strong>, Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Poland </span> <span class=approved-referee__competing-list> <strong>Competing interests:</strong> No competing interests were declared. (for version 1) <br> </span> </li> </ol> </div> </div> </div> </div> <div class="f1r-article-mobile research-layout"> <div class="mobile-sections-divider before-comments"></div> </div> <div id=article-comments class="article-comments padding-bottom-20"> <div class=current-article-comment-section> <h2 class=main-title name=add-new-comment id=add-new-comment> <span class="research-layout f1r-article-mobile-inline valign-middle"> <span class="f1r-icon icon-104_comments size30"></span> </span> <span class=f1r-article-desk-inline>Comments on this article</span> <span class=f1r-article-mobile-inline>Comments (0)</span> <span class="f1r-article-mobile-inline float-right"> <span class="f1r-icon icon-14_more_small"></span> <span class="f1r-icon icon-10_less_small"></span> </span> </h2> </div> <div class="f1r-article-desk-inline referee-report-info-box referee-report-version-box"> Version 1 </div> <div class="f1r-article-mobile research-layout mobile-version-info padding-top-30"> <span class=mversion>VERSION 1</span> <span class=details>PUBLISHED 30 Mar 2017</span> <span class="article-pubinfo-mobile versions-section"> </span> </div> <div class="f1r-article-mobile research-layout margin-top-20 is-centered"> <a href="/login?originalPath=/articles/6-397/v1&scrollTo=add-new-comment" class=register-report-comment-button data-test-id=add-comment_mob> <button class="primary orange extra-padding comment-on-this-report">ADD YOUR COMMENT</button> </a> </div> <a href="/login?originalPath=/articles/6-397/v1&scrollTo=add-new-comment" class="f1r-article-desk register-report-comment-button" data-test-id=add-comment> <span class=contracted></span>Comment </a> </div> </div> </div> <div id=article_main-column class="p-article__sidebar o-layout__item u-1/3 not-expanded js-article-sidebar"> <div class="o-tab p-article__column-toggle-container"> <button class="c-tab c-tab--left js-column-toggle p-article__column-toggle not-expanded " type=button data-target-main=article_main-column data-target-secondary=article_secondary-column><i class="c-tab__icon material-icons u-hide@expanded">keyboard_arrow_left</i><i class="c-tab__icon material-icons u-show@expanded">keyboard_arrow_right</i></button> </div> <div class=p-article__sidebar-content> <div class="p-article__sidebar-scroller js-article-sidebar-scroller"> <section class="p-article__sidebar-view js-article-sidebar-view js-article-sidebar-main u-pt u-pb--8" data-view=peer-review> <div class="o-layout o-layout--flush"> <div class="o-layout__item u-pl"> <h3 class="u-mt--0 u-mb--2 t-h3 u-weight--md u-pl" data-test-id=article_sidebar_heading>Open Peer Review</h3> </div> <div class=o-layout__item> <section class=""> <div class="p-article__sidebar-highlight u-mb--2 u-pr--1"> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md u-mr--1/2">Reviewer Status</h4> <div class="c-referee-status__icons u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=12420-19542></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19889-19545></i> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=19122-19544></i> </div> </div> <div class="o-actions__secondary _mdl-layout"> <div class="c-block-tip p-article__sidebar-tooltip c-block-tip--below c-block-tip--small-arrow c-block-tip--sm-padding"> <button type=button class="c-button c-button--icon c-button--text c-block-tip__toggle"><i class="material-icons c-button--icon__icon">info_outline</i></button> <div class=c-block-tip__content> <p class="t-body u-mt--0 u-mb--0"><em class=u-weight--md>Alongside their report, reviewers assign a status to the article:</em></p> <dl class=c-definitions> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--approved " title=Approved #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved</span></dt> <dd class="c-definitions__description t-caption">The paper is scientifically sound in its current form and only minor, if any, improvements are suggested</dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--reservations" title="Approved with Reservations" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Approved with reservations</span></dt> <dd class="c-definitions__description t-caption"> A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </dd> <dt class="c-definitions__term u-upper t-control u-weight--md u-black--high"><span class="u-ib u-middle"> <i class="c-icn--f1r-icon c-icn--not-approved " title="Not Approved" #data-refInfo=""></i> </span> <span class="u-middle u-ib u-ml--1/2">Not approved</span></dt> <dd class="c-definitions__description t-caption">Fundamental flaws in the paper seriously undermine the findings and conclusions</dd> </dl> </div> </div> </div> </div> </div> <div class="o-layout__item u-mb--1"><h4 class="u-mt--0 u-mb--0 u-ib u-middle t-h4 u-weight--md">Reviewer Reports</h4></div> <table class="c-report-timeline u-mb--2"> <thead class=c-report-timeline__headings> <tr> <th></th> <th class="u-pb--1/2" colspan=3><em class="t-body u-weight--rg">Invited Reviewers</em></th> </tr> <tr class=c-report-timeline__headings-row> <th></th> <th class="c-report-timeline__headings-version p-article__color--dark">1</th> <th class="c-report-timeline__headings-version p-article__color--dark">2</th> <th class="c-report-timeline__headings-version p-article__color--dark">3</th> </tr> </thead> <tbody> <tr class="c-report-timeline__row c-report-timeline__row--selected "> <th class=c-report-timeline__version> <a data-test-id=sidebar_timeline_v1_version href="https://f1000research.com/articles/6-397/v1">Version 1</a><br/> <span class=p-article__color--dark> <span data-test-id=sidebar_timeline_v1_date class=c-report-timeline__date>30 Mar 17</span> </span> </th> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> <td class="c-report-timeline__report c-report-timeline__cell "> <i class="c-icn--f1r-icon c-icn--approved small" title=Approved #data-refInfo=""></i> </td> </tr> </tbody> </table> <div class=o-layout__item> <hr class="c-hr c-hr--low u-mb--2"> </div> </section> </div> <div class=o-layout__item> <div class="u-pl u-pr"> <p class="t-body u-mt--0 u-mb--2"><a href="/browse/faculty-reviews">Faculty Reviews</a> are review articles written by the prestigious Members of <a href="https://facultyopinions.com/prime/home" target=_blank class=in-text-link>Faculty Opinions</a>. The articles are commissioned and peer reviewed before publication to ensure that the final, published version is comprehensive and accessible. The reviewers who approved the final version are listed with their names and affiliations.</p> <ol class="p-article__faculty-referee-list t-caption"> <li> <p class=" u-mt--0 u-mb--1/2"><strong>S. J. Enna</strong>, Research and Graduate Education, Department of Physiology and Pharmacology, Kansas University Medical Center, USA </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Philippe De Deurwaerd&egrave;re</strong>, CNRS, Institut des Maladies Neurodégénératives, France </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> <li> <p class=" u-mt--0 u-mb--1/2"><strong>Andrzej Pilc</strong>, Department of Neurobiology, Institute of Pharmacology, Polish Academy of Sciences, Poland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> <p class=" u-mt--2 u-mb--1/2"><strong>Michal Korostynski</strong>, Department of Molecular Neuropharmacology, Institute of Pharmacology, Polish Academy of Sciences, Poland </p> <div class="c-read-more js-read-more " data-lines=3> <div class="c-read-more__content js-read-more-content "> <p class="u-mt--0 u-mb--0 p-article__color--light"> <strong class=u-weight--md>Competing interests:</strong> No competing interests were declared. </p> </div> <a href="#" class="c-read-more__toggle js-read-more-toggle t-caption"> <span class=c-read-more__expand>View more</span> <span class=c-read-more__contract>View less</span> </a> </div> </li> </ol> </div> </div> <section class="o-layout__item u-pl"> <div class=u-pl> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--2">Comments on this article</h4> <div class=u-mb--4> <p class="u-mt--0 u-mb--1 t-h4"><a class=p-article__color--light href="#article-comments">All Comments</a><span class=" u-ib u-ml--1/2 p-article__color--light">(0)</span></p> <a class=t-h4 href="/login?originalPath=/articles/6-397/v1&scrollTo=add-new-comment" data-test-id=add-comment>Add a comment</a> </div> <hr class="c-hr c-hr--low c-hr--md u-mb--4"> <div class="research-layout f1r-article-desk"> <div class="heading6 c-ribbon-wrapper c-ribbon-wrapper--etoc f1000research "> <div class=c-ribbon-wrapper__body>Sign up for content alerts</div> </div> </div> <div class="research-layout sidebar-sign-up-form f1r-article-desk u-mb--4 "> <form class=js-email-alert-signup action="#" method=POST data-email=tocAlertWeekly> <input type=hidden name=isUserLoggedIn class=js-email-alert-signup-logged-in value=N /> <input type=hidden name=userId class=js-email-alert-signup-user-id value=""/> <input type=hidden name=frequency class=js-email-alert-signup-frequency value=WEEKLY /> <div class="o-actions o-actions--middle"> <div class=o-actions__primary> <input type=email name=emailAddress class="form-input-field js-email-alert-signup-address u-1/1 u-bb" required=required placeholder=Email /> </div> <div class=o-actions__secondary> <div class="_mdl-layout u-ml--1/2"> <button class="mdl-button mdl-js-button mdl-button--colored mdl-button--small mdl-button--filled js-email-alert-signup-submit">Sign Up</button> </div> </div> </div> </form> <div id=sidebar-sign-up-message class="section-text js-email-alert-signup-msg is-hidden">You are now signed up to receive this alert</div> </div> <section class=js-terms-container> <hr class="c-hr c-hr--low c-hr--md u-mb--3"> <h4 class="t-h3 u-weight--md u-mt--0 u-mb--1">Browse by related subjects</h4> <div class="article-subcontainer article-subcontainer--sidebar"> <ul class=js-terms-list></ul> </div> </section> </div> </section> </div> </section> </div> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/read-more.js"></script> <script src="/js/article/article-router.js"></script> <script src="/js/article/article-sidebar.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/article/article-column-toggle.js"></script> </div> </div> </div> </main> <input type=hidden id=_articleVersionUrl value="https://f1000research.com/articles/6-397/v1/"> <div class=research-help id=about-referee-status> <div class="research-layout research-help-content about-referee-status"> <span class="close-research-help dark-cross" title=Close></span> Alongside their report, reviewers assign a status to the article: <div class="cf research-help-row"> <span class="f1r-icon icon-86_approved status-green smaller" title=Approved></span> <span class=research-help-text>Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested</span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-87_approved_reservations status-green smaller" title="Approved with Reservations"></span> <span class=research-help-text>Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. </span> </div> <div class="cf research-help-row"> <span class="f1r-icon icon-88_not_approved status-red small" title="Not Approved"></span> <span class=research-help-text>Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions</span> </div> </div> </div> <div id=datasets-info class=is-hidden> </div> <div class=article-interactive-content-container style="display: none;"> <a name=f-template class=n-a></a> <div class="interactive-content-wrapper padding-20"> <img src="" class=interactive-content-image title="Open the interactive image display"> <div class=interactive-content-title></div> <div class=interactive-content-text></div> <div class="f1r-article-desk interactive-content-ribbon" data-interactive-content-type=R-Script> <div class=interactive-content-label>Adjust parameters to alter display</div> <div class=interactive-content-button></div> </div> <div class="f1r-article-mobile mobile-interactive-note"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div id=article-interactive-omero-container class=article-interactive-omero-container style="display: none;"> <div class=interactive-content-wrapper> <div class="interactive-omero-button omero-content" title="Open the interactive content window." data-interactive-content-type=Omero></div> <div class=has-interactive-content-image> <span class=box-arrow></span> <span class=box-middle>Includes Interactive Elements</span> <span class=box-end></span> </div> <div class="fig panel clearfix" style="margin: 0; padding-bottom: 20px;"> <a name=templatelink class=n-a></a> <a target=_blank href="" class=link-for-omero-image> <img src="" class=interactive-omero-image title="Open the image display window."> </a> <div class=caption> <div class=interactive-content-title></div> <div class=interactive-content-text></div> </div> <div class="is-hidden omero-image-list"></div> </div> <div class="f1r-article-mobile mobile-interactive-note omero"> View on desktop for interactive features <img src="/img/icon/interactive_content.png" class="float-right margin-right-40"/> </div> <div class=clearfix></div> </div> </div> <div class="add-comment-container shadow-box is-hidden" id=save-comment-container> <span id=save-comment-text class=intro-text>Edit comment</span> <textarea id=new-comment name=new-comment class="global-textarea comment margin-bottom margin-top"></textarea> <p><strong>Competing Interests</strong></p> <textarea id=new-competing-interests name=competing-interests class="global-textarea competing-interests margin-bottom check-xss"></textarea> <div class=clearfix></div> <button id=cancelComment type=button class="general-white-orange-button float-right no-background-button margin-left"> Cancel </button> <button id=save-comment-button commentId="" type=button class="general-white-orange-button float-right"> Save </button> <div class=clearfix></div> <div class="green-message margin-top is-hidden comment-is-saved">The comment has been saved.</div> <div class="red-message margin-top is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class="red-message margin-top is-hidden comment-enter-text ucf">Your must enter a comment.</div> <div class="red-message margin-top is-hidden comment-references-error references">References error.</div> </div> <div class="modal-window-wrapper is-hidden"> <div id=conflicts-interests class="modal-window padding-20"> <div class=modal-window__content> <h2 class=h2-title>Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div class="f1r-article-mobile research-layout"> <span class=modal-window-close-button></span> </div> </div> </div> <div class="o-modal c-email-alert-popup js-email-alert-popup is-hidden"> <div class="o-modal__body js-modal-body c-email-alert-popup__inner"> <h3 class=c-email-alert-popup__title>Stay Updated</h3> <p class=c-email-alert-popup__sub>Sign up for content alerts and receive a weekly or monthly email with all newly published articles</p> <p><a href="/register?originalPath=" class="c-email-alert-popup__lnk c-email-alert-popup__button js-email-alert-popup-action">Register with F1000Research</a></p> <p>Already registered? <a href="/login?originalPath=" class="c-email-alert-popup__lnk js-email-alert-popup-action">Sign in</a></p> <p class=c-email-alert-popup__footer><a class="c-email-alert-popup__lnk js-email-alert-popup-cancel" href="#">Not now, thanks</a></p> </div> </div> <div id=addCommentModal role=dialog aria-labelledby=addCommentModal_title aria-describedby=addCommentModal_description> <div class="c-modal js-modal is-closed p-article__add-comment-modal c-modal--xlarge js-article-comment-modal c-modal--scroll "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-bg--2 c-modal--scroll-always "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <div id=addCommentModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div class="js-add-comment-container t-caption u-black--high"> <div class=u-weight--bd>PLEASE NOTE</div> <div class=u-mt--1> <span class="red u-weight--bd">If you are an AUTHOR of this article,</span> please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a &ldquo;User Comment&rdquo;. </div> <div class=u-mt--1> <span class="red u-weight--bd">If you are a REVIEWER of this article,</span> please check that you have signed in with the account associated with this article and then go to your <a href="/my/referee">account</a> to submit your report, please do not post your review here. </div> <div class="u-mt--1 u-mb--1"> If you do not have access to your original account, please <a href="mailto:research@f1000.com">contact us</a>. </div> <p class=no-top-margin>All commenters must hold a formal affiliation as per our <a href="/about/policies#commentspolicy" target=_blank>Policies</a>. The information that you give us will be displayed next to your comment.</p> <p>User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the <a href="/about/legal/usercommenttermsandconditions" target=_blank>User Comment Terms and Conditions</a>. Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available.</p> <div class="comments-note margin-bottom" id=accept-user-comments> <input class=js-add-comment-accept-terms type=checkbox id=acceptedTermsAndConditions name=acceptedTermsAndConditions> I accept the <a href="/about/legal/usercommenttermsandconditions" target=_blank> User Comment Terms and Conditions</a> <span class=required>&nbsp;</span> </div> <div class="default-error margin-top is-hidden comment-accept-conditions utac">Please confirm that you accept the User Comment Terms and Conditions.</div> <div class="research-layout registration-form u-mb--2"> <div class="u-mb--1 u-mt--2"> <strong>Affiliation</strong> </div> <div class=form-field> <input type=text name=institution class="form-input-field check-xss js-add-comment-institution" placeholder="Organization *" autocomplete=off /> <div class="default-error margin-top is-hidden comment-enter-institution institution">Please enter your organisation.</div> </div> <div class=form-field> <input type=text name=place class="form-input-field check-xss js-add-comment-place" placeholder=Place> </div> <div class=form-field> <div class="form-input-wrapper hundred-percent-wide"> <div class="new-select-standard-wrapper half-width inline-display heading10"> <select name=countryId id=country class="form-select-menu smaller js-add-comment-country"> <option value=-1>Country*</option> <option value=840>USA</option> <option value=826>UK</option> <option value=124>Canada</option> <option value=156>China</option> <option value=250>France</option> <option value=276>Germany</option> <optgroup label=-----------------------------------------------></optgroup> <option value=4>Afghanistan</option> <option value=248>Aland Islands</option> <option value=8>Albania</option> <option value=12>Algeria</option> <option value=16>American Samoa</option> <option value=20>Andorra</option> <option value=24>Angola</option> <option value=660>Anguilla</option> <option value=10>Antarctica</option> <option value=28>Antigua and Barbuda</option> <option value=32>Argentina</option> <option value=51>Armenia</option> <option value=533>Aruba</option> <option value=36>Australia</option> <option value=40>Austria</option> <option value=31>Azerbaijan</option> <option value=44>Bahamas</option> <option value=48>Bahrain</option> <option value=50>Bangladesh</option> <option value=52>Barbados</option> <option value=112>Belarus</option> <option value=56>Belgium</option> <option value=84>Belize</option> <option value=204>Benin</option> <option value=60>Bermuda</option> <option value=64>Bhutan</option> <option value=68>Bolivia</option> <option value=70>Bosnia and Herzegovina</option> <option value=72>Botswana</option> <option value=74>Bouvet Island</option> <option value=76>Brazil</option> <option value=86>British Indian Ocean Territory</option> <option value=92>British Virgin Islands</option> <option value=96>Brunei</option> <option value=100>Bulgaria</option> <option value=854>Burkina Faso</option> <option value=108>Burundi</option> <option value=116>Cambodia</option> <option value=120>Cameroon</option> <option value=124>Canada</option> <option value=132>Cape Verde</option> <option value=136>Cayman Islands</option> <option value=140>Central African Republic</option> <option value=148>Chad</option> <option value=152>Chile</option> <option value=156>China</option> <option value=162>Christmas Island</option> <option value=166>Cocos (Keeling) Islands</option> <option value=170>Colombia</option> <option value=174>Comoros</option> <option value=178>Congo</option> <option value=184>Cook Islands</option> <option value=188>Costa Rica</option> <option value=384>Cote d'Ivoire</option> <option value=191>Croatia</option> <option value=192>Cuba</option> <option value=196>Cyprus</option> <option value=203>Czech Republic</option> <option value=180>Democratic Republic of the Congo</option> <option value=208>Denmark</option> <option value=262>Djibouti</option> <option value=212>Dominica</option> <option value=214>Dominican Republic</option> <option value=218>Ecuador</option> <option value=818>Egypt</option> <option value=222>El Salvador</option> <option value=226>Equatorial Guinea</option> <option value=232>Eritrea</option> <option value=233>Estonia</option> <option value=231>Ethiopia</option> <option value=238>Falkland Islands</option> <option value=234>Faroe Islands</option> <option value=583>Federated States of Micronesia</option> <option value=242>Fiji</option> <option value=246>Finland</option> <option value=250>France</option> <option value=254>French Guiana</option> <option value=258>French Polynesia</option> <option value=260>French Southern Territories</option> <option value=266>Gabon</option> <option value=268>Georgia</option> <option value=276>Germany</option> <option value=288>Ghana</option> <option value=292>Gibraltar</option> <option value=300>Greece</option> <option value=304>Greenland</option> <option value=308>Grenada</option> <option value=312>Guadeloupe</option> <option value=316>Guam</option> <option value=320>Guatemala</option> <option value=831>Guernsey</option> <option value=324>Guinea</option> <option value=624>Guinea-Bissau</option> <option value=328>Guyana</option> <option value=332>Haiti</option> <option value=334>Heard Island and Mcdonald Islands</option> <option value=336>Holy See (Vatican City State)</option> <option value=340>Honduras</option> <option value=344>Hong Kong</option> <option value=348>Hungary</option> <option value=352>Iceland</option> <option value=356>India</option> <option value=360>Indonesia</option> <option value=364>Iran</option> <option value=368>Iraq</option> <option value=372>Ireland</option> <option value=376>Israel</option> <option value=380>Italy</option> <option value=388>Jamaica</option> <option value=392>Japan</option> <option value=832>Jersey</option> <option value=400>Jordan</option> <option value=398>Kazakhstan</option> <option value=404>Kenya</option> <option value=296>Kiribati</option> <option value=901>Kosovo (Serbia and Montenegro)</option> <option value=414>Kuwait</option> <option value=417>Kyrgyzstan</option> <option value=418>Lao People's Democratic Republic</option> <option value=428>Latvia</option> <option value=422>Lebanon</option> <option value=426>Lesotho</option> <option value=430>Liberia</option> <option value=434>Libya</option> <option value=438>Liechtenstein</option> <option value=440>Lithuania</option> <option value=442>Luxembourg</option> <option value=446>Macao</option> <option value=807>Macedonia</option> <option value=450>Madagascar</option> <option value=454>Malawi</option> <option value=458>Malaysia</option> <option value=462>Maldives</option> <option value=466>Mali</option> <option value=470>Malta</option> <option value=584>Marshall Islands</option> <option value=474>Martinique</option> <option value=478>Mauritania</option> <option value=480>Mauritius</option> <option value=175>Mayotte</option> <option value=484>Mexico</option> <option value=581>Minor Outlying Islands of the United States</option> <option value=498>Moldova</option> <option value=492>Monaco</option> <option value=496>Mongolia</option> <option value=499>Montenegro</option> <option value=500>Montserrat</option> <option value=504>Morocco</option> <option value=508>Mozambique</option> <option value=104>Myanmar</option> <option value=516>Namibia</option> <option value=520>Nauru</option> <option value=524>Nepal</option> <option value=530>Netherlands Antilles</option> <option value=540>New Caledonia</option> <option value=554>New Zealand</option> <option value=558>Nicaragua</option> <option value=562>Niger</option> <option value=566>Nigeria</option> <option value=570>Niue</option> <option value=574>Norfolk Island</option> <option value=580>Northern Mariana Islands</option> <option value=408>North Korea</option> <option value=578>Norway</option> <option value=512>Oman</option> <option value=586>Pakistan</option> <option value=585>Palau</option> <option value=275>Palestinian Territory</option> <option value=591>Panama</option> <option value=598>Papua New Guinea</option> <option value=600>Paraguay</option> <option value=604>Peru</option> <option value=608>Philippines</option> <option value=612>Pitcairn</option> <option value=616>Poland</option> <option value=620>Portugal</option> <option value=630>Puerto Rico</option> <option value=634>Qatar</option> <option value=638>Reunion</option> <option value=642>Romania</option> <option value=643>Russian Federation</option> <option value=646>Rwanda</option> <option value=654>Saint Helena</option> <option value=659>Saint Kitts and Nevis</option> <option value=662>Saint Lucia</option> <option value=666>Saint Pierre and Miquelon</option> <option value=670>Saint Vincent and the Grenadines</option> <option value=882>Samoa</option> <option value=674>San Marino</option> <option value=678>Sao Tome and Principe</option> <option value=682>Saudi Arabia</option> <option value=686>Senegal</option> <option value=688>Serbia</option> <option value=690>Seychelles</option> <option value=694>Sierra Leone</option> <option value=702>Singapore</option> <option value=703>Slovakia</option> <option value=705>Slovenia</option> <option value=90>Solomon Islands</option> <option value=706>Somalia</option> <option value=710>South Africa</option> <option value=239>South Georgia and the South Sandwich Is</option> <option value=410>South Korea</option> <option value=724>Spain</option> <option value=144>Sri Lanka</option> <option value=736>Sudan</option> <option value=740>Suriname</option> <option value=744>Svalbard and Jan Mayen</option> <option value=748>Swaziland</option> <option value=752>Sweden</option> <option value=756>Switzerland</option> <option value=760>Syria</option> <option value=158>Taiwan</option> <option value=762>Tajikistan</option> <option value=834>Tanzania</option> <option value=764>Thailand</option> <option value=270>The Gambia</option> <option value=528>The Netherlands</option> <option value=626>Timor-Leste</option> <option value=768>Togo</option> <option value=772>Tokelau</option> <option value=776>Tonga</option> <option value=780>Trinidad and Tobago</option> <option value=788>Tunisia</option> <option value=792>Turkey</option> <option value=795>Turkmenistan</option> <option value=796>Turks and Caicos Islands</option> <option value=798>Tuvalu</option> <option value=800>Uganda</option> <option value=826>UK</option> <option value=804>Ukraine</option> <option value=784>United Arab Emirates</option> <option value=850>United States Virgin Islands</option> <option value=858>Uruguay</option> <option value=840>USA</option> <option value=860>Uzbekistan</option> <option value=548>Vanuatu</option> <option value=862>Venezuela</option> <option value=704>Vietnam</option> <option value=876>Wallis and Futuna</option> <option value=905>West Bank and Gaza Strip</option> <option value=732>Western Sahara</option> <option value=887>Yemen</option> <option value=894>Zambia</option> <option value=716>Zimbabwe</option> </select> </div> </div> <div class="default-error margin-top is-hidden comment-enter-country country">Please select your country.</div> </div> </div> <textarea data-test-id=article_add-comment_comment name=new-comment class="js-add-comment-comment comment margin-bottom margin-top"></textarea> <div class="default-error margin-top comment-enter-text comment-error is-hidden ">You must enter a comment.</div> <label class="comments-note u-mt--2 u-mb--2" for=competingInterests_1> <div class="u-mb--1 u-mt--2"><strong data-test-id=article_report-add-comment_competing-interests-title>Competing Interests</strong></div> <p class="u-mb--2 u-mt--0" data-test-id=article_report-add-comment_competing-interests-description>Please disclose any <a href="#article-competing-intersts-policy" class=js-modal-competing-intersts-toggle>competing interests</a> that might be construed to influence your judgment of the article's or peer review report's validity or importance.</p> </label> <div id=article-competing-intersts-policy class=js-article-competing-interests-policy style="display: none;"> <h2 class="h2-title u-mt--0 u-pt--0">Competing Interests Policy</h2> <p> Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: </p> <div class=heading5>Examples of 'Non-Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper.</li> <li class=standard-padding>You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors.</li> <li class=standard-padding>You are a close professional associate of any of the authors (e.g. scientific mentor, recent student).</li> <li class=standard-padding>You work at the same institute as any of the authors.</li> <li class=standard-padding>You hope/expect to benefit (e.g. favour or employment) as a result of your submission.</li> <li class=standard-padding>You are an Editor for the journal in which the article is published.</li> </ol> <div class="heading5 padding-top">Examples of 'Financial Competing Interests'</div> <ol class="numbered-list no-padding"> <li class=standard-padding>You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements.</li> <li class=standard-padding>You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors.</li> <li class=standard-padding>You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on.</li> </ol> </div> <div id=competingInterests_1 class="c-inline-editor js-inline-editor js-form_input u-bb--all u-mb--2 js-comment-competing-interests" data-name=competing-interests data-rows=3> <textarea id=competingInterests_1_input name=competing-interests placeholder="&nbsp;" required=false class="u-hide-visually js-inline-editor_input" tabindex=-1></textarea> <div class="c-inline-editor__editor js-inline-editor_editor o-box c-box o-box--tiny u-bg--11" data-target=competingInterests_1_input role=textbox required=false data-placeholder="&nbsp;" contenteditable=true></div> <span class="c-inline-editor__error js-inline-editor-message">Please state your competing interests</span> </div> <div data-test-id=article_add-comment_saved class="green-message comments is-hidden comment-is-saved">The comment has been saved.</div> <div data-test-id=article_add-comment_error class="default-error comments is-hidden comment-not-added">An error has occurred. Please try again.</div> <div class=clearfix></div> <div class=js-hook></div> </div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" data-test-id=article_add-comment_cancel class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" data-test-id=article_add-comment_post class="c-button c-button--full js-modal__confirm c-button--primary">Post</a> </div> </aside> </div> </div> <style>
                .at-icon-wrapper {
        background-size: 100% !important;
    }
</style> <script src="/js/namespace.js"></script> <script src="/js/constants.js"></script> <script src="/js/utilities.js"></script> <script src="/js/article/alert-signup.js"></script> <script type='text/javascript'>
    var lTitle = "New drugs in psychiatry: focus on new pharmacological...".replace("'", '');
    var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://f1000research.com/articles/6-397/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by ');

    var deliciousUrl = "https://del.icio.us/post?url=https://f1000research.com/articles/6-397/v1&title=" + encodeURIComponent(lTitle);

    var redditUrl = "http://reddit.com/submit?url=https://f1000research.com/articles/6-397/v1" + "&title=" + encodeURIComponent(lTitle);

            linkedInUrl += encodeURIComponent('Caraci F et al.');
    
    var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; 
    var addthis_config = {
            ui_offset_top: offsetTop,
                                    services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com",
            services_custom : [
                {
                    name: "LinkedIn",
                    url:  linkedInUrl,
                    icon:"/img/icon/at_linkedin.svg"
                },
                {
                    name: "Mendeley",
                    url:  "http://www.mendeley.com/import/?url=https://f1000research.com/articles/6-397/v1/mendeley",
                    icon:"/img/icon/at_mendeley.svg"
                },
                {
                    name: "Reddit",
                    url:  redditUrl,
                    icon:"/img/icon/at_reddit.svg"
                },
            ]
        };


    var addthis_share = {
            url: "https://f1000research.com/articles/6-397",
            templates : {
                twitter : "New drugs in psychiatry: focus on new pharmacological targets. Caraci F et al., published by " + 
               "@F1000Research"
       + ", https://f1000research.com/articles/6-397/v1"
            }
        };

    if (typeof(addthis) != "undefined"){
        addthis.addEventListener('addthis.ready', checkCount);
        addthis.addEventListener('addthis.menu.share', checkCount);
    }

        $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter);
    $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url);
    $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url);
    $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url);
    $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url);

    function checkCount(){
        setTimeout(function(){
            $(".addthis_button_expanded").each(function(){
                var count = $(this).text();
                if (count !== "" && count != "0")
                    $(this).removeClass("is-hidden");
                else
                    $(this).addClass("is-hidden");
            });
        }, 1000);
    }
</script> <div id=citeReportModal role=dialog aria-labelledby=citeReportModal_title aria-describedby=citeReportModal_description> <div class="c-modal js-modal is-closed c-modal--large js-cite-report-modal "> <aside class="c-modal__content u-black--high o-box u-pb--0 u-black--high "> <div class=c-modal__close> <button type=button class="c-button c-button--icon c-button--medium c-button--full@hover js-modal__close"><i class="c-button--icon__icon material-icons">close</i></button> </div> <h1 id=citeReportModal_title class="c-modal__title t-h3 u-mt--0 u-mb--2 u-weight--md">How to cite this report</h1> <div id=citeReportModal_description class="c-modal__description js-modal__content t-h4 u-mt--0 u-mb--2 u-black--medium"> <div id="" class=js-report-citation-container>{{reportCitation}}</div> <div class="c-modal__extra-message js-modal__extra-message t-h4 u-black--medium"></div></div> <div class="c-modal__actions o-box__actions"> <a href="#" class="c-button c-button--full js-modal__close c-button--secondary">Cancel</a> <a href="#" title="Copy the current citation details to the clipboard." data-clipboard-target="#referee-report-citation" data-test-id=report_copy-citation_button class="c-button c-button--full js-modal__confirm c-button--primary js-clipboard c-mini-tooltip--above">Copy Citation Details</a> </div> </aside> </div> </div> <script src="/js/referee/new/referee_validators.js"></script> <script src="/js/referee/new/referee_helpers.js"></script> <script src="/js/referee/new/referee_checkbox-input.js"></script> <script src="/js/referee/new/referee_inline-editor.js"></script> <script type="text/javascript">
    $(function(){
        var gaCat = "F1000Research";
        if (gaCat === "") {
            gaCat = $("body").hasClass("wellcome-brand") ? "Wellcome Open Research" : "F1000Research";
        }
        GAHelper.track({category: gaCat, action: "Article Page: New drugs in psychiatry: focus on new pharmacological targets", label: "pageviews"});
        GAHelper.track({category: gaCat, action: "Article Type: Review", label: "Article Page"});
        $(".f1r-article-desk .collection-image").each(function (idx, el) {
            var whatChannel = $(el).find("a").attr("href"),
                channelName = $.trim($(el).parent().find(".collection-detail a").text()),
                gaRef = "(ID: " + whatChannel.replace("/collections/", "") + ") " + channelName;
            GAHelper.track({category: 'ChannelStats', action: "Article Page: New drugs in psychiatry: focus on new pharmacological targets", label: gaRef});
        });
    });
</script> <script>
    $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');});
    $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');});
</script> <script src="/js/article/track_article.js" type="text/javascript"></script> <script type="text/javascript">
    $.get("/articles/acj/10233/11022")
</script> <script type="text/javascript" src="https://d1bxh8uas1mnw7.cloudfront.net/assets/embed.js"></script> <script type="text/javascript" src="/js/app/messenger.js"></script> <script type="text/javascript" src="/js/article/article_mobiles.js"></script> <script src="/js/vendor/clipboard.min.js"></script> <script src="/js/shared_scripts/modal-dialogue.js"></script> <script src="/js/shared_scripts/clipboard.js"></script> <script src="/js/article/thesaurus-terms-display.js"></script> <script>
    new F1000.Clipboard();
    new F1000.ThesaurusTermsDisplay("faculty-reviews", "article", "11022");
</script> <script>
    $(document).ready(function() {
        $( "#frame1" ).on('load', function() {
            var mydiv = $(this).contents().find("div");
            var h     = mydiv.height();
            console.log(h)
        });

        
        var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"),
            titleLivingFigure = tooltipLivingFigure.attr("title");
        tooltipLivingFigure.simpletip({
            fixed: true,
            position: ["-115", "30"],
            baseClass: 'small-tooltip',
            content:titleLivingFigure + "<div class='tooltip-arrow'></div>"
        });
        tooltipLivingFigure.removeAttr("title");

        $("body").on("click", ".cite-living-figure", function(e) {
            e.preventDefault();
            var ref = $(this).attr("data-ref");
            $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200);
        });
        $("body").on("click", ".close-cite-living-figure", function(e) {
            e.preventDefault();
            $(this).closest(".popup-window-wrapper").fadeOut(200);
        });

                $(document).on("mouseup", function(e) {
            var metricsContainer = $(".article-metrics-popover-wrapper");
            if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) {
                $(".article-metrics-close-button").click();
            }
        });

        var articleId = $('#articleId').val();

        if($("#main-article-count-box").attachArticleMetrics) {
            $("#main-article-count-box").attachArticleMetrics(articleId, {
                articleMetricsView: true
            });
        }
    });

    var figshareWidget = $(".new_figshare_widget");
    if (figshareWidget.length > 0) {
        window.figshare.load("f1000", function(Widget) {
            // Select a tag/tags defined in your page. In this tag we will place the widget.
            _.map(figshareWidget, function(el){
                var widget = new Widget({
                    articleId: $(el).attr("figshare_articleId")
                    //height:300 // this is the height of the viewer part. [Default: 550]
                });
                widget.initialize(); // initialize the widget
                widget.mount(el); // mount it in a tag that's on your page
                // this will save the widget on the global scope for later use from
                // your JS scripts. This line is optional.
                //window.widget = widget;
            });
        });
    }
</script>

<script>
    $(document).ready(function () {

        
        var reportIds = {
                           "19542": 0,
                           "19543": 0,
                           "19544": 0,
                           "19545": 0,
                    };

        $(".referee-response-container,.js-referee-report").each(function(index, el) {
            var reportId = $(el).attr("data-reportid"),
                reportCount = reportIds[reportId] || 0;
            $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount);
        });

        var uuidInput = $("#article_uuid"),
            oldUUId = uuidInput.val(),
            newUUId = "5acc7f78-fc53-4196-b713-1438a8488e07";
        uuidInput.val(newUUId);

        $("a[href*='article_uuid=']").each(function(index, el) {
            var newHref = $(el).attr("href").replace(oldUUId, newUUId);
            $(el).attr("href", newHref);
        });

    });
</script>              </div>
        </div>

        
            
            <div class="o-page__footer sticky-email-wrapper">
                
                

                


<footer class="c-footer t-inverted">

    <div class="o-wrapper">
        <div class="o-layout">


                        
            <div class="o-layout__item u-mb--3">
                <div class="c-branding c-branding--research">
                    <img src="/img/research/F1000Research_white.svg" alt="F1000Research">
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <p class="t-h3 u-mt--0 u-mb--0">An innovative open access publishing platform offering rapid publication and open peer review, whilst supporting data deposition and sharing.</p>

            </div>


                        
            <div class="o-layout__item u-2/3@md">

                <span class="c-hr c-hr--thick c-hr--low u-mb--2"></span>

                <div class="o-layout">
                    <nav class="c-footer__nav">

                            <div class="o-layout__item u-3/5@sm u-mb--3">


                                <div class="o-columns o-columns--2">

                                                                            <a href="/browse/articles" class="t-body c-footer__nav-item "      >Browse</a>
                                                                            <a href="/gateways" class="t-body c-footer__nav-item "      >Gateways</a>
                                                                            <a href="/collections" class="t-body c-footer__nav-item "      >Collections</a>
                                                                            <a href="/about" class="t-body c-footer__nav-item "      >How it Works</a>
                                                                            <a href="https://blog.f1000.com/blogs/f1000research/" class="t-body c-footer__nav-item "      >Blog</a>
                                                                            <a href="/contact" class="t-body c-footer__nav-item "      >Contact</a>
                                                                            <a href="/developers" class="t-body c-footer__nav-item u-hide u-show@navbar"      >For Developers</a>
                                                                            <a href="/published/rss" class="t-body c-footer__nav-item "   title="RSS feed of published articles"     >RSS</a>
                                    
                                </div>

                            </div>

                            <div class="o-layout__item u-2/5@sm u-center u-right@sm u-mb--3">

                                <div class="u-hide u-show@lg">
                                    <div class="_mdl-layout">
                                        <a class="mdl-button mdl-js-button mdl-button--inverted mdl-button--no-shadow mdl-js-ripple-effect mdl-button--outline" href="/for-authors/publish-your-research"   data-test-id="footer_submit_research"  >Submit Your Research</a>
                                    </div>
                                </div>

                            </div>

                    </nav>
                </div>

            </div>

            <div class="o-layout__item u-mb--2">
                <div class="c-footer__share">
                        <div class="c-footer__share">
        <span class="c-footer__share-icon" title="Open Access">
            <span class="f1r-icon icon-100_open_access license-icon"></span>
        </span>

        <a class="c-footer__share-icon" href="//creativecommons.org/licenses" target="_blank" title="Creative Commons License CC-BY">
            <span class="f1r-icon icon-116_cc license-icon license-icon-cc"></span>
            <span class="f1r-icon icon-117_ccby license-icon license-icon-cc"></span>
        </a>

        <a class="c-footer__share-icon" href="//creativecommons.org/about/cc0" target="_blank" title="Creative Commons License CC0">
            <span class="f1r-icon icon-118_cco license-icon"></span>
        </a>

    </div>
                </div>
            </div>


                        
            <div class="o-layout__item u-1/3@md u-mb--3">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="c-footer__social u-mt--0 u-mb--0 u-white--low-med">Follow us
                    <a href="https://www.facebook.com/F1000" target="_blank" class="c-footer__social-icon f1r-icon icon-55_footer_facebook"></a>
                    <a href="https://twitter.com/#!/F1000Research" target="_blank" class="c-footer__social-icon f1r-icon icon-56_footer_twitter"></a>
                    <a href="http://www.youtube.com/user/F1000research" target="_blank" class="c-footer__social-icon f1r-icon icon-57_footer_youtube"></a></p>

            </div>


                        
            <div class="o-layout__item u-2/3@md u-right@md">

                <span class="c-hr c-hr--low u-mb--3"></span>

                <p class="t-caption u-white--low-med">&copy; 2012-2020 F1000 Research Ltd. ISSN 2046-1402 | <a href="/about/legal" class="copyrightLegal">Legal</a> | Partner of <a target="_blank" href="http://www.who.int/hinari/en/">HINARI</a>  &bull; <a target="_blank" href="http://crossref.org/">CrossRef</a> &bull; <a target="_blank" href="http://about.orcid.org/">ORCID</a> &bull; <a target="_blank" href="http://www.fairsharing.org">FAIRSharing</a></p>

            </div>
        </div>
    </div>

</footer>            </div>
        
    </div>

            <div class="js-cookie-spacer"></div>
        <div class="cookie-warning">
            <div class="instruction">The F1000Research website uses cookies. By continuing to browse the site, you are agreeing to our use of cookies. <a class="js-scroll-to" href="/about/legal/privacypolicy#use-of-cookies" data-scroll-target="#use-of-cookies">Find out more &raquo;</a></div>
            <div class="close-button"></div>
        </div>
    
    <script>
                    R.templateTests.simpleTemplate = R.template('<p class="$variable.one">$text</p><p class="${variable.two}">$text</p><p class="$!variable.three">$text</p><p class="$!{variable.four}">$text</p><p class="${selector}.five">$text</p>');
            R.templateTests.runTests();
        
        var F1000platform = new F1000.Platform({
            name: "f1000research",
            displayName: "F1000Research",
            hostName: "f1000research.com",
            id: "1",
            editorialEmail: "research@f1000.com",
            infoEmail: "info@f1000.com",
            usePmcStats: true
        });

                    $(function(){R.ui.dropdowns('.dropdown-for-authors, .dropdown-for-about, .dropdown-for-myresearch');});
            // $(function(){R.ui.dropdowns('.dropdown-for-referees');});

            $(document).ready(function () {
                if ($(".cookie-warning").is(":visible")) {
                    $(".sticky").css("margin-bottom", "35px");
                    $(".devices").addClass("devices-and-cookie-warning");
                }
                $(".cookie-warning .close-button").click(function (e) {
                    $(".devices").removeClass("devices-and-cookie-warning");
                    $(".sticky").css("margin-bottom", "0");
                });

                $("#tweeter-feed .tweet-message").each(function (i, message) {
                    var self = $(message);
                    self.html(linkify(self.html()));
                });

                $(".partner").on("mouseenter mouseleave", function() {
                    $(this).find(".gray-scale, .colour").toggleClass("is-hidden");
                });
            });
        
    </script>

            
<div class="sign-in-popup">
	<!-- <a href="#" class="sign-in shadow">Sign in <span class="sign-in-image-active"></span></a> -->
	<a href="#" class="sign-in ${locale}">Sign In <span class="arrow-closed sign-in-arrow-padding arrow-opened"></span></a>
	<div class="sign-in-form">

            <form action="https://f1000research.com/j_spring_oauth_security_check" id="googleOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-397.html"/>
                            <input id="google-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-google" name="system" type="hidden" value="GOOGLE"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="facebookOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-397.html"/>
                            <input id="facebook-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-fb" name="system" type="hidden" value="FACEBOOK"/>
    </form>
            <form action="https://f1000research.com/j_spring_oauth_security_check" id="orcidOAuth" method="post"  target="_top" >
                                    <input class="target-field" type="hidden" name="target" value="/articles/6-397.html"/>
                            <input id="orcid-remember-me" name="_spring_security_oauth_remember_me" type="hidden" value="true"/>
        <input id="system-orcid" name="system" type="hidden" value="ORCID"/>
    </form>
		<form id="sign-in-form" class="login-container" action="https://f1000research.com/login" method="post" name="f">
           <div id="sign-in-form-gfb-popup"></div>

                                                            <input class="target-field" type="hidden" name="target" value="/articles/6-397.html"/>
                            			<input type="text" name="username" id="signin-email-box" class="sign-in-input" placeholder="Email address" autocomplete="email">
			<input type="password" name="password" id="signin-password-box" class="sign-in-input" placeholder="Password" autocomplete="current-password">
			<div class="sign-in-remember">
                <div class="checkbox-wrapper">
    				<input type="checkbox" id="remember-me" name="remember_me" class="checkbox is-hidden">
                </div>
                <span class="checkbox-label">Remember me</span>
			</div>
			<a href="#" class="sign-in-link" id="forgot-password-link">Forgotten your password?</a>
			<div class="sign-in-button-container margin-top margin-left-20 margin-bottom">
				<button type="submit" id="sign-in-button" class="sign-in-buttons general-white-orange-button">Sign In</button>
				<button type="button" id="sign-in-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
				<div class="clearfix"></div>
			</div>
			<div class="sign-in-error">Email or password not correct. Please try again</div>
			<div class="sign-in-loading">Please wait...</div>
		</form>
		<div class="forgot-password-container">
			
<script type="text/javascript">
	$(function(){
		// Note: All the setup needs to run against a name attribute and *not* the id due the clonish
		// nature of facebox...
		$("a[id=googleSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("GOOGLE");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=facebookSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("FACEBOOK");
            $("form[id=oAuthForm]").submit();
        });
        $("a[id=orcidSignInButton]").click(function(event){
            event.preventDefault();
            $("input[id=oAuthSystem]").val("ORCID");
            $("form[id=oAuthForm]").submit();
        });
	});
</script>

<span class="text first">
	If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password.
    <p>The email address should be the one you originally registered with F1000.</p>
</span>
<input name="email" class="sign-in-input" id="email-forgot-password" type="text" placeholder="Email address">
<div class="forgot-password-email-error">
	Email address not valid, please try again
</div>
<div class="forgot-password-google-email-error">
    <p>You registered with F1000 via Google, so we cannot reset your password.</p>
	<p>To sign in, please click <a href="#" id="googleSignInButton">here</a>.</p>
    <p>If you still need help with your Google account password, please click <a href="https://www.google.com/accounts/recovery">here</a>.</p>
</div>
<div class="forgot-password-facebook-email-error">
    <p>You registered with F1000 via Facebook, so we cannot reset your password.</p>
    <p>To sign in, please click <a href="#" id="facebookSignInButton">here</a>.</p>
	<p>If you still need help with your Facebook account password, please click <a href="https://www.facebook.com/recover/initiate">here</a>.</p>
</div>
<div class="clearfix"></div>
<div class="forgot-password-captcha-error">
	Code not correct, please try again
</div>
<div class="clearfix"></div>
<div class="sign-in-button-container margin-left-20 margin-bottom">
	<button type="button" id="sign-in-reset-password" class="sign-in-buttons general-white-orange-button">Reset password</button>
	<button type="button" id="forgot-password-cancel" class="sign-in-buttons sign-in-cancel-button margin-left">Cancel</button>
	<div class="clearfix"></div>
</div>
<span class="text last">
	<a href="mailto:">Email us</a> for further assistance.
</span>
<form action="https://f1000research.com/j_spring_oauth_security_check" id="oAuthForm" method="post" target="_top">
                        <input class="target-field" type="hidden" name="target" value="/articles/6-397.html"/>
                <input id="oAuthSystem" name="system" type="hidden"/>
</form>
			<div class="forgot-password-server-error">Server error, please try again.</div>
			<div class="sign-in-success">
                <p>We have sent an email to <span id="email-value"></span>, please follow the instructions to reset your password.</p>
                <p>If you don't receive this email, please check your spam filters and/or contact .</p>
            </div>
			<div class="sign-in-loading">Please wait...</div>
		</div>

		<div class="sign-in-form-register-section">
			<div class="sign-in-button-container margin-left-20 margin-bottom">
				<a href="/register" title="Register"><button type="button" id="sign-in-register-button" class="sign-in-buttons general-white-orange-button">Register</button></a>
				<div class="clearfix"></div>
			</div>
		</div>

	</div>
</div>

<script type="text/javascript">
$(document).ready(function () {

    signIn.createSignInAsRow($("#sign-in-form-gfb-popup"));

    $(".target-field").each(function () {
        var uris = $(this).val().split("/");
        if (uris.pop() === "login") {
        	$(this).val(uris.toString().replace(",","/"));
        }
    });
});
</script>
        <div id="templateOverlay" class="is-hidden" hidden="hidden">
  <div class="o-overlay js-overlay is-hidden" hidden="hidden"></div>
</div>

<div id="templateExternalMessages" class="is-hidden" hidden="hidden">
  <div class="o-modal o-modal--auto@md js-external-messages is-hidden" hidden="hidden">
    <div class="o-modal__body">
      <section class="c-console">
        <div class="_mdl-layout c-console__bdy js-external-messages-body"></div>
        <footer class="_mdl-layout c-console__ftr o-flex o-flex--reverse js-external-messages-footer">
          <button type="button" class="mdl-button mdl-js-button mdl-button--raised mdl-button--colored c-console__btn js-external-messages-close" data-action="maintenance-close">I Understand</button>
        </footer>
      </section>
    </div>
  </div>
</div>

<script src="https://cdnjs.cloudflare.com/ajax/libs/moment.js/2.22.1/moment.min.js"></script>

<script src="/js/namespace.js"></script>
<script src="/js/constants.js"></script>
<script src="/js/utilities.js"></script>

<script>
                  F1000.ExtenalMaintenanceItems = [
    {
      start: '2018-12-10T14:21:00Z',
      end: '2018-12-13T16:00:00Z',
      msg: 'This site will be down for a short time on XX December. It is advisable not to start any submissions on that day or you may lose your work unless you save regularly.',
      cookieName: 'outage23122018',
      editor: false,
    }
  ];
</script>

<script src="/js/shared_scripts/cookie-helper.js"></script>
<script src="/js/shared_scripts/mdl-helper.js"></script>

<script src="/js/app/external-maintenance.js"></script>

                <script type="text/javascript">
            (function(i,s,o,g,r,a,m){i['GoogleAnalyticsObject']=r;i[r]=i[r]||function(){
            (i[r].q=i[r].q||[]).push(arguments)},i[r].l=1*new Date();a=s.createElement(o),
            m=s.getElementsByTagName(o)[0];a.async=1;a.src=g;m.parentNode.insertBefore(a,m)
            })(window,document,'script','//www.google-analytics.com/analytics.js','ga');

            ga('create', 'UA-5646075-11', 'auto');
            ga('require', 'displayfeatures');
            ga('send', 'pageview');
        </script>
        
                <script type="text/javascript" src="/js/app/research.analytics.js"></script>

        <!-- Start of HubSpot Embed Code -->
        <script type="text/javascript" id="hs-script-loader" async defer src="//js.hs-scripts.com/4475190.js"></script>
        <!-- End of HubSpot Embed Code -->
    
            <script src="https://my.hellobar.com/4e0495c6f18cbd68731a1dc1978195a144e767ba.js" type="text/javascript" charset="utf-8" async="async"></script>
    </body>

</html>